

National Cancer Institute

CURRICULUM VITAE

PERSONAL INFORMATION

Name: John Milburn Jessup, M.D.

Birth Place: New Haven, CT

Citizenship: U.S. Citizen

Business Addresses: Chief, Diagnostics Evaluation Branch
Cancer Diagnosis Program, DCTD
National Cancer Institute
Executive Plaza North 6040
6130 Executive Boulevard
Rockville, MD 20852

Adjunct Investigator
Laboratory of Experimental Carcinogenesis
National Cancer Institute
Building 37, Room 4146A
Bethesda, MD 20892

Business Phone (NCI): (301) 435-9010

E-Mail (NIH): jessupj@mail.nih.gov

Facsimile (NCI): (301) 402-7819

Foreign Languages Spoken: None

LICENSURE

Texas License	Initial Date 1980	Expiration Date 2/28/2010
Maryland License		Expiration Date 9/30/2010
{Also Emergency Physician, Maryland Bioterrorism Unit}		

CONTROLLED SUBSTANCE

Texas	Expiration Date 2/28/2009
Maryland	Expiration Date 10/31/2010
DEA	Expiration Date 12/31/2011

CERTIFICATION

American Board of Surgery

Certificate No. 26687 Initial Date 1981 Renewal Dates 1991, 2001 Expiration Date 2011

American Heart Association

Advanced Cardiovascular Life Support (ACLS)

Expiration Date Nov. 14, 2010

Basic Life Support (BLS)

Expiration Date Feb. 14, 2009

EDUCATION

UNDERGRADUATE:

1964-1968	Yale University	B.A.	English
	New Haven, CT	1968	

GRADUATE:

1968-1972	New York Medical College	M.D.	Medicine
	New York, NY	1972	

POSTDOCTORAL TRAINING:

Internship and Residencies:

1972-1974	New York Hospital-Cornell Medical Center	Internship and
	New York, New York	Junior Assistant Resident
	Chief: Paul A. Ebert, M.D.	

1974-1976	Surgery Branch, National Cancer Institute	Clinical Associate
	National Institutes of Health, Bethesda, Maryland	
	Chief: Steven A. Rosenberg, M.D., Ph.D.	

1977-1980	Department of General Surgery	General Surgery Resident
	University of Texas Medical School at Houston	
	Houston, Texas	
	Chief: Stanley J. Dudrick, M.D.	

Research Fellowships:

1976-1977	Frederick Cancer Research Center	Visiting Scientist
	Basic Research Program, Litton Bionetics, Inc.	
	Fort Detrick, Frederick, Maryland	
	Director: Michael G. Hanna, Jr., Ph.D.	

MILITARY SERVICE

Lt. Cdr.	USPHS Active Duty 1974 – 1976 National Cancer Institute Reserves 1976 – 1980
Lt. Col.	Maryland Defense Force 2005 - 2006 Physician, 10 th Medical Regiment, MD Army National Guard

PROFESSIONAL EXPERIENCE

Academic Positions

1972-1974	New York Hospital-Cornell Medical Center, New York, NY	Resident in Surgery
1974-1976	National Cancer Institute, National Institutes of Health, Bethesda, MD	Clinical Associate, Surgery Branch
1977-1980	University of Texas Medical School at Houston, Houston, TX	Clinical Fellow in Surgery
1980-1981	U.T.M.D. Anderson, Houston, Texas Hospital and Tumor Institute, Houston, TX	Faculty Associate in Surgery
1981-1986	University of Texas M.D. Anderson Hospital and Tumor Institute, Houston, TX	Assistant Professor of Surgery and Immunology
1986-1989	University of Texas M.D. Anderson Cancer Center, Houston, TX	Associate Professor of Surgery and Immunology
1989-1997	Harvard Medical School, Boston, MA	Associate Professor of Surgery
1997-2000	University of Pittsburgh, Pittsburgh, PA	Professor of Surgery with Tenure
2000-2001	University of Texas Health Science Center at San Antonio, San Antonio, TX	Professor of Surgery with Tenure
2001	University of Texas Health Science Center at San Antonio, San Antonio, TX	Adjunct Prof. of Cellular & Structural Biology
2001	University of Texas Health Science Center at San Antonio, San Antonio, TX	Member, Graduate School Faculty
2001- 2006	Georgetown University Medical Center	Professor of Oncology and Surgery, Tenure Track
2004-2006	MedStar Research Institute	Senior Scientist
2005-2006	Cancer Diagnosis Program, DCTD, NCI, Rockville, MD	Special Assistant, (80% IPA),
2006-Present	Georgetown University medical Center	Adjunct Professor, Oncology
2006-Present	Cancer Diagnosis Program, DCTD, NCI Rockville, MD	Chief, Diagnostics Evaluation Branch

Hospital Appointments:

1980-1981	Departments of General Surgery and Immunology, U.T.M.D. Anderson Hospital and Tumor Institute, Houston, TX	Faculty Associate
-----------	--	-------------------

1981-1986	Department of General Surgery, U.T.M.D. Anderson U.T.M.D. Anderson Hospital and Tumor Institute, Houston, TX	Assistant Surgeon
1986-1989	Department of General Surgery, U.T.M.D. Anderson U.T.M.D. Anderson Cancer Center, Houston, TX	Associate Surgeon
1989-1997	Beth Israel Deaconess Medical Center, Boston, MA	Active Staff
1989-1997	Dana-Farber Cancer Institute, Boston, MA	Consultant in Surgery
1990-1997	New England Baptist Hospital, Boston, MA	Provisional Staff
1990-1997	Cardinal Cushing General Hospital, Brockton, MA	Provisional Staff
1990-1997	Goddard Memorial Hospital, Stoughton, MA	Courtesy Staff
1991-1997	Southwood Community Hospital, Norfolk, MA	Courtesy Staff
1997-2000	University of Pittsburgh Medical Center, Pittsburgh, PA	Active Staff
2000-2001	University Hospital System, San Antonio, TX	Active Staff
2002-2005	Georgetown University Hospital, Washington, D.C.	Active Staff
2007-	National Naval Medical Center, Bethesda, MD	Provisional Staff

HONORS AND AWARDS

1971	Alpha Omega Alpha Honor Society
1972	Lange Publishing Company Medical Student Award
1979-1980	Fellowship Training Grant, American Cancer Society
1994	Excellence Award, National Aeronautics and Space Agency, Biotechnology
1999-	Roll of Honour, Union Internationale Contra le Cancer,
1999	Team Excellence Award, National Aeronautics and Space Agency, Contributions to Construction of ISS
2000	Chairman, Metabolic Pathology Study Section, NIH
2003	Special Space Flight Achievement Award from the Space and Life Sciences Directorate for the Expedition 7 CBOSS-FDI Team.
2004	Special Space Flight Achievement Award from the Space and Life Sciences Directorate for the Expedition 8 CBOSS-FDI Team.
2005-2006	Maryland Governor's Citations for Katrina Urgent Care Work with MDDF- Team Leader
2006	National Cancer Institute Certificate of Appreciation for Katrina Relief Work
2006	National Cancer Institute Merit Award for service on the Biospecimen Coordinating Committee
2007	Spaceflight Sustained Achievement Award - Team: CBOSS-FDI, NASA
2007	Medal of Honor - Distinguished Alumnus, New York Medical College
2008	National Cancer Institute Plain Language Award for NIH-NASA MOU

PROFESSIONAL SOCIETIES

1971-	Member, Alpha Omega Alpha Honor Society
1978-	Member, American Association for Cancer Research
1978-	Member, American Association for the Advancement of Science
1980-1989	Member, Harris County Medical Society
1980-1983	Member, New York Academy of Sciences
1981-Present	Fellow, American College of Surgeons
1981-1993	Member, American Medical Association
1981-1989	Member, Association for Academic Surgery
1981-1989	Member, Houston Surgical Society
1981-1989	Member, Texas Medical Association
1984-Present	Member, Society for Surgical Oncology
1984-Present	Member, American Society of Clinical Oncology
1987-Present	Member, Society of University Surgeons
1988-2000	Member, Aerospace Medical Association
1988-Present	Member, Society for Biological Therapy
1988-1990	Member, Southern Medical Association
1990-2001	Member, Metastasis Research Society
1992-Present	Member, The Surgical Biology Club
1992-2002	Member, Commission on Cancer, American College of Surgeons
1992-1999	Member, Space Medicine Branch, Aerospace Medical Association
1993-2003	Member, American Society for Cell Biology
1993-Present	Member, American Institute of Aeronautics and Astronautics (AIAA)
1997-2004	Member, Connective Tissue Oncology Society
2002-2008	Member, American Society for Biochemistry and Molecular Biology

PUBLIC SERVICE

1977-1980	Consultant, Basic Research Program, Frederick Cancer Research Center, Frederick, MD
1985-1987	Sub-Editor, Section of Immunology, Year Book of Cancer, Year Book Publ. Co.
1986-1989	Consultant, Kelsey-Seybold Clinic, Houston, TX
1987-1989	Consultant, Bionetics Research, Inc., Gaithersburg, MD
1988-	Consultant, National Aeronautics and Space Administration (NASA), Life Sciences Division, Code SD4, Clear Lake, TX
1988-1993	Editorial Board, Journal of Clinical Oncology
1989-1992	Member, Veteran's Administration (VA), Merit Review Board for Oncology
1991-1995	Editorial Board, Year Book of Cancer, Year Book Publishing Company
1991	Guest Editor, Volume One, "Conservative Management of Rectal Cancer", Surgical Oncology Clinics of North America, B. Cady (Ed.)
1984-1986	Member, Association for Academic Surgery, Program Committee
1986-1989	Ad hoc member, Large Bowel Working Group, Organ System Coordinating

	Committee, NIH
1988-1991	Member, Aerospace Medical Association Scientific Program Committee
1991	Member, Ad hoc Special Review Group for Upper Gastrointestinal Cancer, (SPORE), National Institutes of Health
1991	Site Visitor, Program-Project Review (NIH), Wistar Institute,
1991	Member, Program Committee, American Society of Clinical Oncology
1991-1993	Member, Committee for Government Relations, Society for Surgical Oncology
1992-1996	Ad Hoc Member, Metabolic Pathology Study Section, NIH
1992	Member, Special Review Committee for RFA-CA92-12 "Clinical Correlates in Solid Tumors", NIH
1992	Member, NASA Biotechnology Science Discipline Working Group, NASA, Washington, DC
1992-2002	Member, Commission on Cancer, American College of Surgeons
1993	Member, Special Review Committee, NIH, for RFA-CA93-16, "Gastrointestinal SPORE"
1993	Member, Site Visitor, Program-Project Review, Thomas Jefferson University,
1993-1994	Member, Shuttle-MIR Working Group, NASA, Washington, D.C.
1993	Biotechnology Facility Review Panel, Space Station, NASA-Johnson Space Center, Houston, TX
1993	Chairman, Fourth Annual International Workshop on CEA/PSG Family Members, Boston, MA
1993	Vice Chairman, National Cancer Database Committee, Commission on Cancer, American College of Surgeons
1993-1994	Member, Local Arrangements Committee, Society for Surgical Oncology
1993-1997	Ad hoc reviewer, VA Merit Review Board for Oncology
1994-1997	Chairman, National Cancer Data Committee, Commission on Cancer, American College of Surgeons
1994-Present	Member, American Society of Clinical Oncology, Tumor Marker Expert Panel, Washington, D.C.
1994-1998	PDQ External Advisory Board, National Cancer Institute
1994-2003	Chairman, Biotechnology Discipline Working Group, NASA
1994	Consultant, College of American Pathology, Tumor Marker Panel, Utah
1994-2000	Member, Microgravity Research and Applications Subcommittee, NASA, Washington, D.C.
1995	Chairman, Biotechnology and Microgravity Workshop 1995, Society of In Vitro Biology,
1995	Consultant, College of American Pathologists, Guidelines for Esophageal and Gastric Carcinoma and Gastrointestinal Lymphoma,
1995	Lead Cell Scientist, Engineering Design Unit-1, STS 70 (This is first microgravity

	flight of the NASA-Bioreactor) July, 1995.
1996	Chairman, Biotechnology and Microgravity Workshop, Society of In Vitro Biology, San Francisco, June, 1996.
1996-2000	Member, Metabolic Pathology Study Section, NIH
1996	Chairman, External Review of Biological Specimen Temperature Controller (BSTC) and Bioreactor, NASA/JSC Biotechnology, Houston, TX, February 1996.
1996	Member, PO1 Site Visit Team, University of California Davis Prostate Cancer Program, de Vere White, Principal Investigator, Rockville, MD.
1996-1998	Member, Cancer and Leukemia Group B, Solid Tumor Correlative Sciences Core Committee.
1996-2002	Chairman, Colorectal Carcinoma Patient Care Evaluation Study, Commission on Cancer, American College of Surgeons.
1996-1998	Consultant, National Action Plan for Breast Cancer, Informed Consent and Tissue Banking.
1997	Lead Cell Scientist, BDS-2, STS 85 (This is second microgravity flight of the NASA-Bioreactor) August, 1997.
1998	Chairman, Biotechnology and Microgravity Workshop, Society of In Vitro Biology, Las Vegas, June, 1998.
1996-1999	Member, Clinical Research, Cancer Control and Epidemiology Advisory Committee, American Cancer Society, Atlanta, GA.
1997- 1997	Member, Space Station Utilization Advisory Subcommittee, NASA Co-Chair, Special Interest Group, "Three-Dimensional Growth" 37th Annual Meeting, American Society for Cell Biology
1997	Member, ZRG2 SSS-1 Special Study Section, NIH, Bethesda, MD.
1998	Co-Chair, Special Interest Group, "NASA: Controversies in Space-Based Research", 38th Annual Meeting, ASCB, Washington, D.C.
1999	Chairman, Colorectal Carcinoma Prognostic Marker Subcommittee American Joint Committee on Cancer
1998-2002 1999-2005	Member, Clinical Training Committee, Society of Surgical Oncology Editorial Board, Tumour Biology
1999-2003	Chairman, Space Station Utilization Advisory Subcommittee, NASA
2000-2001	Chairman, Metabolic Pathology Study Section, NIH, Bethesda, MD
2000-2001	Member, GI Committee, Southwest Oncology Group
2000-2004	Co-Chairman, Program for the Assessment of Clinical Cancer Tests (PACCT), NCI, NIH, Bethesda, MD (Advisory Board for the Cancer Diagnosis Program)
2000-Present	Chairman, Hindgut Task Force, American Joint Committee on Cancer (AJCC)
2000-2003	Member, Biological and Physical Research Advisory Committee (BPRAC), NASA
2000-2003	Member, Physical Science Advisory Subcommittee, NASA
2001	Principal Investigator, Cell Scientist, BSTC Experiment, Expedition 3, International Space Station, NASA

2001-2003	Member, Colorectal Cancer Pathology Committee for Common Data Elements, CTEP, NCI
2001-Present	Member, Expert Panel on Tumour Markers for TNM Staging, Union Internationale Contre Cancre, Geneva, Switzerland
2002-2005	Member, GI Core Committee, Cancer and Acute Leukemia Group B
2002	Member, Review Panel, Familial Colorectal Cancer Registries, NCI, NIH
2002	Member, Small Business Innovative Research Study Section, NIH ZRG1 SSS-1(10)B
2002-2003	Member, Biotechnology Facility Scientific Concept Review Team, Houston TX
2002-Present	Membership Committee, American Society of Clinical Oncology
2002-Present	Chair, Colon Cancer Working Group, PACCT, CDP, NCI, NIH
2002-2006	Scientific & Ethical Advisory Board, Indivumed, Hamburg, Germany
2003	Principal Investigator, Cell Scientist, BSTC Experiment, Expedition 5, International Space Station, NASA
2003-2005	Ad Hoc, Cancer Biomarker Study Section (CBSS), NIH
2003-2004	Principal Investigator, FDI-CBSS, Expeditions 7, 8 & 9, International Space Station, NASA
2004-2006	Editor-In-Chief, <i>International Journal of Gastrointestinal Cancer</i>
2005-2006	Special Assistant, Cancer Diagnosis Program, DCTD, NCI, NIH
2005-2006	Member, Maryland Defense Force (Subunit of MD Army National Guard), Team Leader, Hurricane Katrina Medical Response Team, Operation Lifeline, Gretna, LA
2005	Member, Biorepositories Coordinating Committee, Office of Biorepositories and Biospecimen Research, OD, NCI
2006	Chair, Consent Tracking Working Group, caTISSUE, caBIG
2006-	Chief, Diagnostics Evaluation Branch, CDP, DCTD, NCI, NIH
2006-	Coordinator, 18q LOH Validation Project, NCI
2006-	Member, Biospecimen Working Group, Center for Cancer Research, NCI, NIH
2006-	Member, Colorectal Review Panel, College of American Pathologists
2006-	Chair, Hindgut Task Force, American Joint Committee on Cancer
2007	Faculty, EORTC-NCI-ASCO 4 th Annual Meeting on Cancer Biomarkers
2007-	Member, Clinical Performance Subcommittee, AACR-FDA-NCI Cancer Biomarkers Collaborative (CBC)
2007	Session Leader, NASA Lunar Biomedical Research Workshop, Clear Lake, TX, June 27-29, 2007
2007	Session Co-Chair, Custodianship and Ownership Issues in Biospecimen Research NCI Workshop (to be held Oct 4-5, 2007, Bethesda, MD)
2008-	Institutional Point of Contact, NIH-NASA Interaction for the National Laboratory on the International Space Station
2008	Co-Chair, Cancer Stem Cells as Markers for Prognosis and Response to Therapy,

	NCI Workshop, Jan 17-18, 2008, Bethesda, MD.
2008-	Adjunct Investigator, Laboratory of Experimental Carcinogenesis, CCR, NCI
2008-	Coordinator, BCR-ABL Pilot Study – Phase I, NCI, Cancer Diagnosis Program
2008-	Co-Chair, Provisional Clinical Opinions, American Society of Clinical Oncology, Washington, DC.
2008-	Co-Chair, American Society of Clinical Oncology, Tumor Marker Expert Panel, GI Cancer Markers, Washington, DC.
2008-	NCI Liaison, Biomarker Task Force, Investigational Drug Steering Committee, NCI

VISITING PROFESSORSHIPS/LECTURES

1982	Department of General Surgery, University of Missouri at Kansas City, Kansas City, MO	Visiting Professor
1991	Eastern Maine Medical Center, Bangor, ME	Visiting Professor
1991	Dartmouth Medical Center, Hanover, NH	Curts Visiting Professor
1991	University of Vermont, Department of Surgery Burlington, VT	Visiting Professor
1992	Ontario Cancer Institute, Toronto, Ontario	Visiting Faculty
1992	St. Luke's Hospital, New Bedford, MA	Visiting Professor
1993	McGill University and Universite de Montreal, Combined Oncology Program	Visiting Professor
1994	Creighton University, Omaha, NB	William A. Albano Lecturer
1994	Southern CA Division, American Cancer Society	Visiting Oncology Professor
1995	Eastern Maine Medical Center, Bangor, ME	Visiting Professor
1995	"Medical Spin-Offs of the NASA Biotechnology Program". Joint NASA-AIAA-DOD Conference on Medical Benefits of Space Research, Houston, TX.	Keynote Address
1996	Eastern Maine Medical Center, Bangor, ME	Visiting Professor
1997	Eastern Maine Medical Center, Bangor, ME	Visiting Professor
1998	Eastern Maine Medical Center, Bangor, ME	Visiting Professor
1999	99th Congress of Japanese Surgical Society, Fukuoka, Japan	Invited Lecturer
1999	Case Western Reserve School of Medicine Cleveland, OH	Visiting Professor
2000	AIAA Conference on Use of the International Space Station, Houston, TX	Invited Lecturer
2002	Plenary Session, Deutsche Bank Healthcare	Invited Lecturer

2002	Symposium, "Advances in Colorectal Carcinoma"	
	Schafer Lecture, "From Bench To Bed: The Use Of Translational Research To Help Patients with Pancreatic Cancer", Georgetown University Medical Center, Washington, DC	Invited Lecturer
2002	"IL-6, Is it important for colorectal metastasis?"	Invited Lecturer
	Special Seminar, Roswell Park Cancer Institute, Buffalo, NY Nov.25, 2002.	
2002	Reduction in apoptosis and enhancement of differentiation in microgravity cell culture, Presented at the American Society for Cell Biology Annual Meeting, San Francisco CA, Dec. 17, 2002	Invited Lecturer
2003	Multidisciplinary Management of Colorectal Liver Metastases. Surgical grand Rounds, INOVA Fairfax Hospital, Jan 15, 2003	Invited Lecturer
2004	What's New in Colorectal Carcinoma?	Invited Lecturer
	American College of Physicians, Central American Chapter Panama City, Panama Jan 30, 2004	
2004	Update in Pancreatic Carcinoma	Invited Lecturer
	American College of Physicians, Central American Chapter Panama City, Panama Jan 31, 2004	
2004	Role of D2 Node Dissection and Adjuvant Therapy of Gastric Cancer, American College of Physicians, Central American Chapter Panama City, Panama Jan 31, 2004	Invited Lecturer
2005	Carcinoembryonic Antigen: Or How I Learned to Love a Tumor Marker, Surgical Grand Rounds, Georgetown University Hospital, Washington, D.C.	Invited Lecturer
2005	Implications of Ethnicity, Age, and Gender On the Outcomes of Stage III Colon Cancer in Community Practice, Colorectal Cancer Disparities Conference, Meharry-Vanderbilt Conference, Nov. 4, 2005	Invited Lecturer
2008	Pluripotent Transcription Factors and CEA in Anoikis and Chemotherapy-induced Apoptosis, S. Frisch, Host, West Virginia University, Jan 23, 2008.	Invited Lecturer
2009	Molecular Diagnostics Laboratories (MoDEL): A Program to Support Cancer Biomarker Clinical Assay Development Meeting, San Diego, Jan 28, 2009	Invited Lecturer Biomarker Assay
2009	The BCR-ABL qRT-PCR Assay: Status of a Molecular Diagnostic that is a Current Standard of Care Tri-Molecular Medicine Conference, San Francisco, Feb. 26, 2009	Invited Lecturer

UNIVERSITY SERVICE

U.T.M.D. Anderson Cancer Center:

1984	Computer Committee
1984	Colon Working Group
1984-1985	Tissue Committee, Infection Control Committee
1985-1988	Chairman, Medical Records Committee
1986-1989	Chief, Gastrointestinal Surgery Section
1986-1989	Chief, Blue Surgical Service
1987-1988	Promotions Committee, Department of General Surgery
1987-1988	Research Committee

New England Deaconess Hospital

1990-1995	Co-Director, Surgical Oncology Research Training Fellowship.
1990-1996	Medical Records Committee
1990-1996	Institutional Review Board
1991-1993	Director, Second Opinion Cancer Clinic, Goddard Memorial Hospital, Stoughton, Massachusetts
1993-1995	Co-Director, New England Deaconess-Southwood Community Hospital Second Opinion Cancer Clinic, Norfolk, Massachusetts (This is the former Pondville State Cancer Hospital)
1993-1996	Surgical Director, Deaconess Nashoba Oncology Clinic, Ayer, Massachusetts
1994-1996	Chairman, Colon Cancer Integrated Clinical Pathway
1995-1996	Patient Medical Education Committee

Beth Israel Deaconess Medical Center

1995-1997	Director, Surgical Oncology Research Training Fellowship
1996-1997	Research Computing Subcommittee of the Computing Resources Committee
1996-1997	Clinical Investigation, New Procedures and new Forms of Therapy Committee
1996-1997	Medical Records Committee
1996-1997	Genetics Testing Subcommittee of the Clinical Investigation Committee

CareGroup Health System:

1997-1997	Founder, Bone and Soft Tissue Sarcoma Center, The Bone and Joint Institute, The New England Baptist Hospital.
-----------	---

UPMC Presbyterian Hospital:

1998-2000	UPCI Protocol Review Committee
1999-2000	Institutional Review Board Subcommittee A
1999-2000	University of Pittsburgh Physicians Policy Committee
1999-2000	University of Pittsburgh Presbyterian Hospital Procedure Committee
1999-2000	University of Pittsburgh Shadyside Hospital Cancer Committee

University of Pittsburgh Cancer Institute:

1997-2000 Director, GI Oncology Program
 1999-2000 Deputy Director, Division of Surgical Oncology
 1999-2000 Member, Executive Committee of the University of Pittsburgh Cancer Institute
 1999-2000 Member, Clinical Information Committee, UPCI

University of Texas Health Science Center at San Antonio:

2000-2001 Chief, Section of Surgical Oncology
 2000-2001 Director, Cancer Prevention and Risk Assessment Clinic, Cancer Therapy & Research Center, San Antonio, TX
 2000-2001 Institutional Principal Investigator, National Surgical Adjuvant Breast and Bowel Project, UTHSCSA
 2000-2001 Institutional Co-Principal Investigator, Southwest Oncology Group (SWOG), UTHSCSA
 2000-2001 Member, GI Committee, SWOG

San Antonio Cancer Institute (SACI):

2000-2001 Program Leader, GI Oncology Program
 2000-2001 Member, Executive Committee (SACI)

Lombardi Cancer Center

2002-2006 Clinical Co-Chair, Clinical Research Committee
 2002-2006 Chair, Data and Safety Monitoring Committee
 2004-2006 Clinical Informatics, Histopathology and Tissue Shared Resource

National Cancer Institute

2005-Present Member, Biorepositories Coordinating Committee (BCC), OD
 2006-Present Member, Repository Evaluation, Informatics and Ethical, Legal Access Subcommittees of BCC
 2006-Present Member, Biorepository Working Group, CCR, OD
 2008-Present Chair, Specimen Use Committee, BCC, OBBR, OD

TEACHING ACTIVITIES

A. Classroom/Laboratory:

Year	Setting	S*/L**	Hrs./Wk.	Wks/Yr.
1980-1984	Lecturer, Melanoma and Sarcoma, General Surgery Course, UTMDACC, Houston, TX	MS/G	3	3

1981-1984	Lecturer, Introductory Immunology, Microbiology Course, First Year Medical Students, UTMSH, Houston, TX	MS/G	3	3
1982-1986	Lecturer, Breast Cancer, Course for Oncologic Nurses, Department of Nursing, UTMDACC, Houston, TX	NS/U	3	1
1985-1989	Lecturer, Advanced Tumor Immunology Course 4.25.3, UTMSH, Houston, TX	GS/G	3	1
1990-1991	Tutor, Patient/Doctor I, Harvard Medical School, Boston, MA	MS/G	2	30
1993	Instructor, "Modern Surgical Oncology for the General Surgeon", Harvard Medical School, Boston, MA	MS/P	1	1
1994	Instructor, "Modern Surgical Oncology for the General Surgeon", Harvard Medical School, Boston, MA	MS/P	1	1
1994	Faculty, Advanced Basic Science Course, "Biology of Solid Tumor Progression", Harvard Medical School, Boston, MA	MS/G	4	2
1996	Instructor, "Modern Surgical Oncology for the General Surgeon", Harvard Medical School, Boston, MA	MS/P	1	1
1996	Director and Faculty, Advanced Basic Medical Science Course, "Biology of Solid Tumor Progression", Harvard Medical School, Boston MA. Lectures: "Molecular Biology of Colonic Neoplastic Transformation and Progression", "Growth Factors in Neoplastic Transformation of the Large Bowel", "Differentiation and Transformation", "The Role of Angiogenesis in Colorectal Carcinoma".	MS/G	4	4

1997	Director and Faculty, Advanced Basic Medical Science Course, SU537.12, "Biology of Solid Tumor Progression", Harvard Medical School, Boston MA. Lectures: "From mucosal change to polyp to tumor", "Growth Factors in Neoplastic Transformation of the Large Bowel", "Tumor Differentiation", and "Angiogenesis in Colorectal Carcinoma".	MS/G	4	4
1998-2000	Mentor, Third year medical students in General Surgery, University of Pittsburgh School of Medicine	MS/G	2	45
1998	Facilitator, IAMS course, Second Year Medical Students, University of Pittsburgh School of Medicine	MS/G	8	5
2002	Instructor, Tumor Biology 508, Cell Cycle, Georgetown University Medical Center	GS	2	2
2002	Instructor, Phar-530, APC and the β Catenin Pathway, Georgetown University Medical Center	GS	2	2
2003	Instructor, Tumor Biology 508, Cell Cycle, Georgetown University Medical Center	GS	2	2
2003	Lecturer, Senior Residents Conference, Georgetown University Hosp. Dept. of Surgery, 8/5/03- Familial Colon Cancer Syndromes	R	2	1
2003	Lecturer, Senior Residents Conference, Georgetown University Hosp. Dept. of Surgery, 8/27/03 – Rectal Cancer	R	2	1
2004	Instructor, Tumor Biology 508 Spring Semester, Cell Cycle, Georgetown University Medical Center	GS	2	1
2004	Instructor, Tumor Biology 508 Fall Semester, Cell Cycle, Georgetown University Medical Center	GS	4	1
2004	Instructor, Gross Anatomy, Abdomen and Pelvis, Georgetown University Medical Center	MS	8	2

2004 Educator of the Day, Department of Surgery, R & MS 3 1
 Georgetown University Medical Center,
 Gastric Neoplasms and GISTs, 11/2/2004

B. Clinical Teaching (ward, clinic, operating room, community):

Year	Setting	S*/L**	Wks./Yr.	Hrs./Wk.
1980- Present	Ward, Operating Room, Clinic	MS/P & R	~45	20

*SCHOOL: Allied Health (AH) **LEVEL: Undergraduate (U)
 Dental School (DS) Resident (R)
 Graduate School (GS) Postgraduate (P)
 Medical School (MS) Graduate (G)
 Nursing School (NS)

C. Instructional Development

1. Formal Study to Improve Teaching Abilities:

American Cancer Society Course on Public Speaking, 1987, Houston, TX.

2. Current Research Concerning Teaching (e.g., development of curriculum or teaching materials, methods, evaluation, etc.):

None

3. Bibliography Concerning Teaching (e.g., textbook contributions and articles related to the topic of teaching. This also listed in Bibliography.):

Telford GL, Bland KI, Flynn TC, Popp MB, Wetstein L. Jessup JM, Kirklin JK, Hoover HC Jr, Bessey PQ, Baker CC, Gaskill HV III, Ricotta JJ, Naji A. Writing a scientific abstract. Current Surgery. 1988; 45:454-8.

4. Media and Software Developed:

Jessup, J.M. Videotape for Cancer Wise Speakers Bureau on Male Cancers. U.T. M.D. Anderson Cancer Center. 1985.

Jessup, J.M., Ota. D.M. Videotape on Rectal Sphincter Preservation Techniques. `U. T. M.D.

Anderson Cancer Center. 1986

Jessup, JM, The *Annual Meeting* Oncogene (Colon and Pancreatic Cancer). Educational Program. American College of Surgeons. 1993;12-15.

Jessup J.M. Lead Cell Science Investigator, Videotape on the Performance of EDU-1, an engineering flight test of a space-based bioreactor, STS-70, National Aeronautics and Space Administration, 1996.

Jessup JM, Menck H, Clive RE. The Role of the National Cancer Data Base in the Care of the Cancer Patient. Manual for the International Education Program of the Commission on Cancer, American College of Surgeons, Chicago, IL, 1997.

Jessup, JM. Interview local NBC affiliate in Washington, DC as a Principal Investigator of Cell Biology experiment on ISS and on the occasion of the launch of STS-108, Dec. 4, 2001.

Jessup, JM. Interview for PBS special "Secrets of the Sequence: Cells in Space" as Principal Investigator for a cell biology experiment on ISS, Dec. 5, 2001.

D. Masters' Thesis and Ph.D. Dissertations Directed, Membership on Supervising Committees, and Postdoctoral Fellows Supervised:

Graduate Student Advisory Committees (2 candidates- J. Hutchins and M. Glassky), M.D. Anderson Hospital and Tumor Institute, Houston, Texas

Research Tutorials:

1987 G. LeKander, Carbohydrate structure of carcinogen-induced colon cancers.
1988 L. Tsui, T cell Western banding techniques.

Research Fellows:

1984-1985 Janet G. Hoagland, M.D., Research Fellow, University of Texas, M.D. Anderson Cancer Center. Currently in private practice, Houston, Texas

1987-1989 Richard B. Hostetter, M.D., Research Fellow, University of Texas, M.D. Anderson Cancer Center. Currently Clinical Associate Professor, Department of Surgery, Indiana University School of Medicine

1992-1993 J. C. Kim, M.D., Research Fellow, Harvard University; Surgical Oncology Research Fellow, Shields Warren Radiation Laboratory, Boston, MA. Currently Associate Professor, Department of Surgery, University of Ulsan and Asan Medical Center,

National Medical School, Seoul, Korea

- 1992-1994 S. Ishii, M.D., Research Fellow, Harvard University; Surgical Oncology Research Fellow, Shields Warren Radiation Laboratory, Harvard University, Boston, MA. Currently, Associate Professor, First Department of Surgery, Tohoku University, Sendai, Japan
- 1994-1996 T. Mizoi, M.D., Research Fellow, Harvard University; Surgical Oncology Research Fellow, Shields Warren Radiation Laboratory, Boston, MA. Currently, Assistant Professor, First Department of Surgery, Tohoku University, Sendai, Japan.
- 1995-1996 Y. Shoji, M.D., Research Fellow, Harvard University; Surgical Oncology Research Fellow, Shields Warren Radiation Laboratory, Boston, MA. Currently, Associate Professor, University of Tokyo, Tokyo, Japan.
- 1996-1997 K. Edmiston, M.D., Research Fellow, Harvard University; Surgical Oncology Research Fellow, Shields Warren Radiation Laboratory, Boston, MA. Currently, private practice in Fairfax, VA.
- 1997-1998 H. Waller-Herrmann, Genetics Counselor Training Program, University of Pittsburgh Medical Center. Dr. Jessup is Mentor for Ms. Waller-Herrmann's thesis on the association between somatic mutations in the APC gene and outcome in colorectal carcinoma.
- 1998-2000 D-C. Fang, M.D., Postdoctoral Fellowship, Laboratory of Gastrointestinal Oncology Research, University of Pittsburgh Cancer Institute. From Third Military Medical Hospital, Chongqing, PRC.
- 2002-2005 L. Laguinge, Ph.D., Postdoctoral fellowship, Lombardi Cancer Center
- 2002-2003 J. Kauh, MD, K-12 Oncology Research Fellow, Lombardi Cancer Center. Currently Assistant Professor of Medical Oncology at Emory University, Atlanta, GA.
- 2003- 2006 R. Samara, M.S., Graduate Student, J. M. Jessup - Mentor, Georgetown University Received Ph.D. on 10 July 2006, Currently Post-Doctoral Fellow, S. Khlief, Mentor, Vaccine Program, Navy-NCI
- 2003-2004 A. Salesiotis, M.D., Clinical Pharmacology Fellow, Georgetown University
- 2004-2005 M. Swift, Graduate thesis committee, A. Wellstein - Mentor
- 2004-2005 I. Cotarla, Graduate thesis committee, P. Furth – Mentor
- 2008- Present L. Espinoza, Post-Doctoral Fellow, LEC, NCI

SCHOLARSHIP AND RESEARCH

A. Research Grants:

Peer-Reviewed

Source (NIH, VA, DOD, etc.): NIH R01 CA42857-18
 Title: "Metastatic Potential of Colorectal Carcinoma".
 Period: 1-1-06 to 12-31-11
 Direct Costs/Current Year/Total: ~\$195,0000 a year
 Role (PI, Co-Investigator, PI 20% Effort

Source (NIH, VA, DOD, etc.): NIH R01 CA42857
 Title: APRC Supplement to "Metastatic Potential of Colorectal Carcinoma".
 Period: 8-1-02 to 5-31-04
 Direct Costs/Current Year/Total: ~\$80,0000 a year
 Role (PI, Co-Investigator, PI 15% Effort

Source (NIH, VA, DOD, etc.): NASA NAG 8-1366
 Title: "Differentiation and Gene Expression of MIP-101 Carcinoma Cells"
 Period: 11-1-01 to 9-30-05
 Direct Costs/Current Year/Total: \$110,000
 Role (PI, Co-Investigator, PI 30% Effort

Source (NIH, VA, DOD, etc.): NASA NAG 8-1360
 Title: "Growth, Metabolism, and Differentiation of MIP-101 Carcinoma Cells"
 Period: 06-1-97 to 12-31-02
 Direct Costs/Current Year/Total: \$150,000
 Role (PI, Co-Investigator, PI 20% Effort

Source (NIH, VA, DOD, etc.): NIH U10
 Title: NSABP Institutional Support Grant
 Period: 7/96- 6/04
 Direct Costs/Current Year/Total: ~\$80,000
 Role (PI, Co-Investigator, PI for UTHSCSA 10% Effort

Source (NIH, VA, DOD, etc.): NIH U24 CA7814
 Title: "Texas Cancer Genetics Consortium"
 Period: 7-1-00 to 6-30-03
 Direct Costs/Current Year/Total: ~\$74,000
 Role (PI, Co-Investigator, PI for UTHSCSA 10% Effort

Source (NIH, VA, DOD, etc.): NIH R01 CA42857
 Title: "Metastatic Potential of Colorectal Carcinoma".
 Period: 5-1-00 to 04-30-05
 Direct Costs/Current Year/Total: ~\$150,0000 a year
 Role (PI, Co-Investigator, PI 30% Effort

Source (NIH, VA, DOD, etc.): NIH R01 CA42857
 Title: APRC Supplement to "Metastatic Potential of Colorectal Carcinoma".
 Period: 7-1-00 to 6-30-02
 Direct Costs/Current Year/Total: ~\$120,000 a year
 Role (PI, Co-Investigator, PI 15% Effort

Source (NIH, VA, DOD, etc.): SACI Pilot Project Development Grant
 Title: "Development of Biomarkers in Colorectal Carcinoma".
 Period: 10-1-00 to 9-30-02
 Direct Costs/Current Year/Total: ~\$20,000 a year
 Role (PI, Co-Investigator, PI 15% Effort

Source (NIH, VA, DOD, etc.): NASA NAG 9-835
 Title: "Growth, Metabolism, and Differentiation of MIP-101 Carcinoma Cells"
 Period: 8-1-95 to 1-31-00
 Direct Costs/Current Year/Total: ~\$150,000 Total Cost
 Role (PI, Co-Investigator, PI 10% Effort

Source (NIH, VA, DOD, etc.): NIH P01 CA44704
 Title: Project 5, "Evaluation of Markers and Prognosis in Colorectal Cancer"
 Period: 5-1-96 to 4-30-00
 Direct Costs/Current Year/Total: ~\$110,000 per year
 Role (PI, Co-Investigator, Project Leader 15% Effort

Source (NIH, VA, DOD, etc.): NIH PO1 CA44704
 Title: "The Pathobiology of Colorectal Cancer"
 Period: 05-01-96 to 08-15-97
 Direct Costs/Current Year/Total: ~\$1,100,000 direct cost per year
 Role (PI, Co-Investigator, PI, 15% Effort

Source (NIH, VA, DOD, etc.): NIH UO1-CA56422
 Title: "Chemoprevention of Colorectal Cancer by Omega-3 Fatty Acids"
 Period: 5-1-92 to 4-30-95
 Direct Costs/Current Year/Total: ~\$150,000 direct cost per year
 Role (PI, Co-Investigator, Co-Investigator, 15% Effort

Source (NIH, VA, DOD, etc.): NIH T32 CA09580
 Title: "Surgical Oncology Research Training Grant"
 Period: 5-1-95 to 8-15-97
 Direct Costs/Current Year/Total: ~\$180,000 direct cost per year
 Role (PI, Co-Investigator, PI, 5% Effort

Other

Source : 91-0403-54 Immunomedics, Inc. Warren, NJ
Title: "Detection of Colorectal Cancer by Diagnostic Imaging of Fab' Fragment of the Anti-CEA Antibody Immu-4 labeled Tc-99m."
Period: 01/91 to 04/94
Direct Costs/Current Year/Total: \$20,000
Role (PI, Co-Investigator, PI, 5% Effort

B. Publications

1. Refereed Articles

1. Jessup JM, Cohen MH, Tomaszewski MM, Felix EL. Effects of murine tumors on delayed hypersensitivity to dinitrochlorobenzene. I Description of anergy caused by transplanted tumors. J Natl Cancer Inst. 57:1077-84, 1976.
2. Jessup JM, Riggs C, Cohen MH. Enhancement of tumor growth by dinitrochlorobenzene (DNCB). Surg Forum. 27:136, 1976.
3. Jessup JM, Cohen MH. Effects of murine tumors on delayed hypersensitivity to dinitrochlorobenzene. II Transitory delayed hypersensitivity in tumor-bearing mice. J Natl Cancer Inst. 59:1221-6, 1977.
4. Jessup JM, Riggs CS, Hanna MG Jr. The influence of pre-existing tumor immunity on BCG-immunotherapy of guinea pigs with both regional and disseminated tumor. Cancer Res. 37:2565-73, 1977.
5. Kripke ML, Lofgreen JS, Beard J, Jessup JM, Fisher MS. In vivo immune response of mice during carcinogenesis by ultraviolet radiation. J Natl Cancer Inst. 59:1277-80, 1977.
6. Cohen MH, Jessup JM, Felix EL, Hume RB, Weese JL, Herberman RB, Rosenberg SA. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: A prospective study of intralesional BCG versus intralesional DNCB. Cancer. 41:2456-63, 1978.
7. Lill PH, Jessup JM, Kripke ML. Accelerated growth by syngeneic tumors in mice treated with methylcholanthrene. Int J Cancer. 21:511-5, 1978.
8. Felix EL, Jessup JM, Cohen MH. Severe complications of intralesional BCG in an unsensitized patient: Case report and clinical implications. Arch Surg. 113:893-6, 1978.

9. Jessup JM, Hanna N, Palaszynski E, Kripke ML. Mechanisms of depressed reactivity to dinitrochlorobenzene and ultraviolet-induced tumors during ultraviolet carcinogenesis in BALB/c mice. *Cellular Immunol.* 38:105-15, 1978.
10. Lin S-N, Jessup JM, Floyd M, Wang TPF, Van Buren CT, Caprioli R, Kahan BD. Quantitation of plasma azathioprine and 6-mercaptopurine levels in renal transplant patients. *Transplantation.* 29:290-4, 1980.
11. Jessup JM, Pellis NR, Kahan BD. The spleen as a source of nonspecific suppressor cells in the tumor-bearing mouse. *J Surg Res.* 28:460-5, 1980.
12. Jessup JM. Splenic trapping as a mechanism for hyporesponsiveness to dinitrochlorobenzene (DNCB) in tumor-bearing (TB) mice. *Surgical Forum.* 31:424-6, 1980.
13. Jessup JM, Macek CM, Kahan BD, Pellis NR. Effect of murine tumors upon delayed hypersensitivity to dinitrochlorobenzene III. In vivo activity of the nonspecific suppressor cell. *J Immunol.* 127:2183-7, 1981.
14. Jessup JM, Kahan BD, Pellis NR. Mechanisms of immunosuppression in tumor-bearing mice: A multifactorial analysis. *Cancer.* 49:1158-67, 1982.
15. Jessup JM, Kahan BD, Pellis NR. Effect of murine tumors upon delayed hypersensitivity to dinitrochlorobenzene IV. Inhibition of elicitation of delayed hypersensitivity. *J Surg Res.* 32:322-8, 1982.
16. Jessup JM, Kahan BD, Pellis NR. Nonspecific suppressor cell activation by soluble factors extracted from tumors. *Surg Forum.* 33:376-8, 1982.
17. Wiseman C, Jessup JM, Smith TL, Hersh E, Bowen J, Blumenschein G. Inflammatory breast cancer treated with surgery, chemotherapy and allogeneic tumor cell/BCG immunotherapy. *Cancer.* 49:1266-71, 1982.
18. Jessup JM, Kahan BD, Pellis NR. Soluble suppressor factors isolated from murine tumors mimic T-suppressor factor. *Surg Forum.* 34:402-4, 1983.
19. Jessup JM, Kahan BD, LeGrue SJ, Rutzky L, Pellis NR. Soluble factors from murine and human tumors induce suppressor cells. *J Surg Res.* 36:631-8, 1984.
20. Ota DM, Jessup JM, Babcock GF, Kirschbaum L, Mountain CF, McMurtrey MJ, Copeland EM. Immune function during intravenous administration of a soybean oil emulsion. *J Parenteral*

Enteral Nutr. 9:23-7, 1985.

21. Jessup JM, LeGrue SJ, Kahan BD, Pellis NR. Induction of suppressor cells by a tumor-derived suppressor factor. *Cellular Immunol.* 93:9-25, 1985.
22. Jessup JM, Babcock GF. Lymphoproliferative response to autologous tumor-associated antigens correlates with good prognosis in patients with colorectal carcinoma. *Surg Forum.* 36:384-5, 1985.
23. Murray JA, Jessup K, Romsdahl M, Raymond K, Ayala A, Carrasco H, Wallace S, Jaffe N, Benjamin R, Plager C, Papadoupoulos N, Chawla S. Limb-salvage surgery in osteosarcoma: Early experience at M.D. Anderson Hospital and Tumor Institute. *Cancer Treat Symp.* 3:131-7, 1985.
24. Fastenberg NA, Buzdar AU, Montague ED, Jessup JM, Martin RG, Hortobagyi GN, Blumenschein GR. Management of inflammatory carcinoma of the breast: A combined modality approach. *Am J Clin Onc.* 8:134-41, 1985.
25. Fidler IJ, Jessup JM, Fogler WE, Staerckel R, Mazumder A. Activation of tumoricidal properties in peripheral blood monocytes of patients with colorectal carcinoma. *Cancer Res.* 46:994-8, 1986.
26. Giavazzi R, Campbell DE, Jessup JM, Cleary K, Fidler IJ. Metastatic behavior of tumor cells isolated from primary and metastatic human colorectal carcinoma implanted into thymic nude mice. *Cancer Res.* 46:1928-33, 1986.
27. Jessup JM, McBride CM, Ames FC, Guarda L, Ota DM, Romsdahl MM, Martin RG. Active specific immunotherapy of Dukes B₂ and C colorectal carcinoma: Comparison of two doses of the vaccine. *Cancer Immunol Immunother.* 21:233-9, 1986.
28. Hoagland JG, Scroggins S, Giavazzi R, Campbell D, Jessup JM. Tumor-derived suppressor factors (TDSFs) in normal and neoplastic colon and rectum. *J Surg Res.* 40:467-74, 1986.
29. Giavazzi R, Jessup JM, Campbell DE, Walker SM, Fidler IJ. Experimental nude mouse model of human colorectal cancer liver metastasis. *JNCI.* 77:1303-8, 1986.
30. Jessup JM, Morikawa K. Model of metastasis of human colorectal carcinoma. *The Cancer Bulletin.* 39:192-5, 1987.
31. Jessup JM, Qi K-F, Kanellopoulos K, Campbell DE, Cleary KR, Hickey CM, Reading CL,

Savage HE. Expression of autoantigens on human colorectal carcinomas: Implications for a generic vaccine. *Arch Surg.* 122:1435-9, 1987.

32. Hutchins JT, Reading CL, Giavazzi R, Hoagland J, Jessup JM. Distribution of mono-, di- and tri-o-acetylated sialic acids in normal and neoplastic colon. *Cancer Res.* 48:483-9, 1988.
33. Jessup JM, Giavazzi R, Campbell D, Cleary K, Morikawa K, Fidler IJ. Growth potential of human colorectal carcinoma in nude mice: Association with the preoperative serum concentration of carcinoembryonic antigen in patients. *Cancer Res.* 48:1689-92, 1988.
34. Morikawa K, Walker SM, Jessup JM, Fidler IJ. In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. *Cancer Res.* 48:1943-8, 1988.
35. Jessup JM, Qi K-F, Kanellopoulos K, Cleary K, Hickey C, Reading CL. Ulex Europaeus Type I agglutinin detects carcinoembryonic antigen in extracts of human colorectal carcinoma. *J Cell Biochem.* 37:193-202, 1988.
36. Hostetter RB, Cleary KR, Jessup JM. Transitional mucosa: Cause or result of human colon carcinogenesis? *Surg Forum.* 39:168-70, 1988.
37. Morikawa K, Walker SM, Nakajima M, Pathak S, Jessup JM, Fidler IJ. The influence of organ environment on the growth selection and metastasis of human colon cancer cells in nude mice. *Cancer Res.* 48:6863-71, 1988.
38. Telford GL, Bland KI, Flynn TC, Popp MB, Wetstein L, Jessup JM, Kirklin JK, Hoover HC Jr, Bessey PQ, Baker CC, Gaskill HV III, Ricotta JJ, Naji A. Writing a scientific abstract. *Current Surgery.* 45:454-8, 1988.
39. McCready DR, Ota DM, Rich TA, Thielvoldt D, Jessup JM. Prospective phase I trial of conservative management of low rectal lesions. *Arch Surg.* 124:67-70, 1989.
40. Hsu TC, Johnston DA, Cherry LM, Ramkissoon D, Schantz SP, Jessup JM, Winn RJ, Shirley L, Furlong C. Sensitivity to genotoxic effects of bleomycin in humans: Possible relationship to environmental carcinogenesis. *Int J Cancer.* 43:403-9, 1989.
41. Jessup JM, Giavazzi R, Campbell D, Cleary KR, Morikawa K, Hostetter R, Atkinson EN, Fidler IJ. Metastatic potential of human colorectal carcinomas implanted into nude mice: prediction of clinical outcome in patients operated upon for cure. *Cancer Res.* 49:6906-10, 1989.

42. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. *Nature*. 342:705-8, 1989.
43. Kroll SS, Pollock R, Jessup JM, Ota D. Transpelvic rectus abdominis flap reconstruction of defects following abdominal-perineal resection. *Am Surg*. 55:632-7, 1989.
44. Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y, Vogelstein B. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. *Science*. 244:217-21, 1989.
45. Patt YZ, Lamki LM, Shanken J, Jessup JM, Charnsangavej C, Ajani JA, Levin B, Merchant B, Halverson C, Murray JL. TI Imaging with indium 111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE-025 of recurrent colorectal or carcinoembryonic antigen-producing cancer in patients with rising serum carcino-embryonic antigen levels and occult metastases. *J Clin Oncol*. 8:1246-54, 1990.
46. Graham RA, Garnsey L, Jessup JM. Local excision of rectal carcinoma. *Am J Surg*. 160:306-12, 1990.
47. Hostetter RB, Campbell DE, Chi K, Kerckhoff S, Cleary KR, Ullrich S, Thomas P, Jessup JM. Carcinoembryonic antigen enhances metastatic potential of human colorectal carcinoma. *Arch Surg*. 125:300-4, 1990.
48. Hostetter RB, Augustus LB, Mankarious R, Chi K, Fan D, Toth C, Thomas P, Jessup JM. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. *J Natl Cancer Inst* 82:380-5, 1990.
49. Wagner HE, Thomas P, Wolf BC, Zamcheck N, Jessup JM, Steele GD Jr. Characterization of the tumorigenic and metastatic potential of a poorly-differentiated human colon cancer cell line. *Invasion Metastasis*. 10:253-66, 1990.
50. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, Willson JK, Hamilton S, Vogelstein B. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. *Cancer Res*. 50:7717-22, 1990.
51. Steele G Jr, Busse P, Huberman MS, LeClair JM, Falchuk ZM, Mayer RJ, Bothe A Jr, Ravikumar TS, Stone M, Jessup JM. A pilot study of sphincter-sparing management of adenocarcinoma of the rectum. *Arch Surg* 126:696-701, 1991; discussion:701-2.

52. Chi K, Jessup JM, Frazier ML. Predominant expression of mRNA coding for nonspecific cross-reacting antigen in colorectal carcinomas. *Tumour Biology* 12:298-308, 1991.
53. Ajani JA, Ota DM, Jessup JM, Ames FC, McBride C, Boddie A, Levin B, Jackson DE, Roh M, Hohn D. Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy. *Cancer* 68:1501-1506, 1991.
54. Goodwin TJ, Jessup JM, Wolf DA. Morphological differentiation of colon carcinoma cell lines HT-29 and HT-29KM in rotating wall vessels. *In Vitro Cellular and Developmental Biology*. 28A:47-60, 1992.
55. Ishii S, Ford R, Thomas P, Steele G, Jessup JM. CD44 mediates adhesion of colorectal carcinoma to basement membrane and extracellular matrix. *Surgical Forum* 63:450-3, 1992.
56. Jessup JM, Goodwin TJ and Spaulding G. Prospects for use of microgravity-based bioreactors to study three dimensional host-tumor interactions in human neoplasia. *J Cell Biochem.* 51:290-300, 1993.
57. Jessup JM, Petrick AT, Toth CA, Ford R, Meterissian S, O'Hara CJ, Steele GS Jr, Thomas P. Carcinoembryonic antigen: enhancement of liver colonisation through retention of human colorectal carcinoma cells. *Brit J Cancer.* 67:464-470, 1993.
58. Jessup JM, Steele G Jr, Mayer RJ, Posner M, Busse P, Cady B, Stone M, Jenkins R, Osteen R. Neoadjuvant therapy for unresectable pancreas adenocarcinoma. *Arch Surg.* 128:559-564, 1993.
59. Patt YZ, Podoloff DA, Curley S, Smith R, Badkhamkar VA, Lamki LM, Jessup JM, Hohn DC. Monoclonal antibody imaging in patients with colorectal cancer and increasing levels of serum carcinoembryonic antigen. *Cancer.* 71:4293-4297, 1993.
60. Mori M, Staniunas RJ, Barnard GF, Jessup JM, Steele GD Jr, Chen LB. The significance of carbonic anhydrase expression in human colorectal cancer. *Gastroenterology.* 105:820-826, 1993.
61. Barnard GF, Staniunas RJ, Mori M, Puder M, Jessup MJ, Steele GD, Jr., Chen LB. Gastric and hepatocellular carcinomas do not overexpress the same ribosomal protein messenger RNAs as colonic carcinoma. *Cancer Research.* 53:4048-4052, 1993.
62. Ishii S, Ford R, Thomas P, Nachman A, Steele, Jr, G, Jessup, JM. CD44 participates in the adhesion of human colorectal carcinoma cells to laminin and type IV collagen. *Surg Onc.* 2:255-

264, 1993.

63. Jessup JM and Goodwin TJ. Simulated microgravity improves production of colonic growth factors. AIAA Technical Paper, 93:0431, 1993.
64. Andrews CW Jr, Jessup JM, Goldman H, Hayes DF, Kufe D, O'Hara CJ, Steele GD Jr. Localization of tumor-associated glycoprotein DF3 in normal inflammatory and neoplastic lesions of the colon. *Cancer*. 72:3185-3190, 1993.
65. Jessup JM, Kim JC, Thomas P, Ishii S, Ford R, Shively JE, Durbin H, Stanners CP, Fuks A, Zhou H, Hansen HJ, Goldenberg DM, Steele G Jr. Adhesion to carcinoembryonic antigen by human colorectal carcinoma cells involves at least two epitopes. *Int J Cancer*. 55:262-268, 1993.
66. Mori M, Barnard GF, Staniunas RJ, Jessup JM, Chen LB and Steele, Jr, GD. Prothymosin-alpha mRNA expression correlates with that of c-myc in human colon cancer. *Oncogene*. 8:2821-2826, 1993.
67. Mori M, Kakeji Y, Adachi Y, Moriguchi S, Maehara Y, Sugimachi K, Jessup JM, Chen L and Steele G. The prognostic significance of proliferating cell nuclear antigen (PCNA) in clinical gastric cancer. *Surgery*. 113:683-690, 1993.
68. Jessup JM, Brown K, Ishii S, Ford R, Goodwin TJ, Spaulding GF. Simulated microgravity does not alter epithelial cell adhesion to matrix and other molecules. *Adv Space Res* 14:71-76, 1994.
69. Ishii S, Steele G Jr, Ford R, Paliotti G, Thomas P, Andrews C, Hansen H, Goldenberg DM, Jessup JM. Normal colonic epithelium adheres to carcinoembryonic antigen and type IV collagen. *Gastroenterology* 106:1242-1250, 1994.
70. Stone MD, Kane R, Bothe A, Jessup JM, Cady B, Steele GD. Intraoperative ultrasound of the liver at time of colorectal resection. *Arch Surg* 129:431-435, 1994.
71. Steele GD, Jessup JM, Winchester DP, Murphy GP, Menck HR. Clinical highlights from the National Cancer Data Base:1995. *CA Cancer J Clin* 45:102-111, 1995.
72. Thomas P, Gangopadhyay A, Steele G Jr, Andrews C, Nakazato H, Oikawa S, Jessup JM. The effect of transfection of the CEA gene on the metastatic behavior of the human colorectal cancer cell line MIP-101. *Cancer Letters* 92:59-66, 1995.
73. Ohannesian DW, Dafna L, Thomas P, Jessup JM, Fukuda M, Gabius HJ, Lotan R. Carcinoembryonic Antigen and Other Glycoconjugates Act as Ligands for Galectin-3 in Human

Colon Carcinoma Cells. *Cancer Research* 55:2191-2199, 1995.

74. Steele GD, Jr and Jessup, JM. Colorectal Cancer. In: National Cancer Data Base: *Annual Review of Patient Care 1995*. Atlanta, GA; American Cancer Society, pp.66-83, 1995.
75. Jessup JM, Lavin PT, Andrews CW Jr., Loda M, Mercurio A, Minsky BD, Mies C, Cukor B, Bleday R, Steele G, Jr. Sucrase-Isomaltase is an Independent prognostic marker for human colorectal carcinoma. *Dis. Colon Rect.* 38:1257-1264, 1995.
76. Ishii S, Mizoi T, Kawano K, Cay O, Thomas P, Nachman A, Ford R, Shoji, Kruskal JB, Steele G Jr, Jessup JM. Implantation of human colorectal carcinoma cells in the liver studied by in vivo fluorescence videomicroscopy. *Clin & Exp Mets* 14:153-164, 1996.
77. Jessup JM and Graeme-Cook FM. Case Records of the Massachusetts General Hospital: a 32-year old woman with subcostal pain and a left hepatic mass. *N Engl J Med* 334:176-182, 1996.
78. Jessup JM and Graeme-Cook FM. Letter to The Editor. *N Engl J Med* 334:1479, 1996.
79. Jessup JM, McGinnis LS, Murphy GP, Winchester DP, Fremgen A, Menck HR, Eyre H. Clinical Highlights from the National Cancer Data Base: 1996. *CA Cancer J Clin* 46:185-192, 1996.
80. Jessup JM, McGinnis LS, Steele Jr. GD, Menck HR, Winchester DP. National Cancer Data Base. Report on Colon Cancer. *Cancer* 78:918-26, 1996.
81. Bast RC, Desch CE, Ravdin P, Smith TJ, and ASCO Expert Panel. Clinical Practice Guidelines for the Use of Tumor Markers in Breast and Colorectal Cancer: Report of the American Society of Clinical Oncology Expert Panel. *J. Clinical Oncology*, 14:2843-2877, 1996.
82. Hayes DF, Bast RC, Desch CE, Fritsche Jr. H, Kemeny NE, Jessup JM, et al. Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers. *J Natl Cancer Inst* 88:1456-66, 1996.
83. Huang YC, Jessup JM, Forse RA, Flickner S, Pleskow D, Anastopoulos HT, Ritter V, Blackburn GL. n-3 fatty acids decrease colonic epithelial cell proliferation in high-risk bowel mucosa. *Lipids* 31 Suppl:S313-7, 1996.
84. Mizoi T, Ishii S, Shoji Y, Ford R, Nachmn A, and Jessup JM. A novel CD44V3-10 isoform in human colorectal carcinoma is a hyaluronate receptor and inhibits tumor growth. *Surg. Forum* 47:510-512, 1996.

85. Shoji Y, Mizoi T, Edmiston K, Nachman A, Ford R, and Jessup JM. Hepatic sinusoidal endothelial cells inhibit colorectal carcinoma cell proliferation through a nitric oxide mechanism. *Surg. Forum* 47:526-529, 1996.
86. Shibata D, Reale MA, Lavin P, Silverman M, Fearon ER, Steele G, Jessup JM, Loda M, Summerhayes IC. The DCC Protein and Prognosis in Colorectal Cancer. *N. Engl. J. Med.* 335:1727-32, 1996.
87. Fogt F, Nikulasson ST, Holden JA, Alder SA, Hallgrimsson J, Jessup JM, O'Brien MJ, Lavin PT, Goldman H. Topoisomerase II-alpha Expression in Normal, Inflammatory and Neoplastic Conditions of the Gastric and Colonic Mucosa. *Mod Pathol* 10:296-302, 1997.
88. Loda M, Cukor B, Tam SW, Lavin PT, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. *Nature Medicine.* 3:231-234, 1997.
89. Jessup JM, Menck HR, Fremgen A, Winchester DP. Diagnosing Colorectal Carcinoma: Clinical and Molecular Approaches. *CA Cancer J Clin* 47:70-92, 1997.
90. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM, Kolodner R. Methylation of the *hMLH1* promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair defective human tumor cell line. *Cancer Res.* 57:808-811, 1997.
91. Lise M, Loda M, Fiorentino M, Mercurio AM, Summerhayes IC, Lavin PT, Jessup JM. Association Between Sucrase-Isomaltase (SI) and P53 Expression in Colorectal Cancer. *Ann. Surgical Oncol.* 4:176-183, 1997.
92. Bleday R, Breen E, Jessup JM, Burgess A, Sentovich SM and Steele Jr. G. Prospective evaluation of local excision for small rectal cancers. *Dis. Colon Rectum* 40:388-392, 1997.
93. Jessup JM, Brown D, Fitzgerald W, Ford RD, Nachman A, Goodwin TJ, Spaulding G. Induction of Carcinoembryonic Antigen Expression in a Three-Dimensional Culture System. In *Vitro Cell. Dev. Biol. - Animal* 33:352-357, 1997.
94. Menck HR, Jessup JM, Eyre HJ, Cunningham MP, Fremgen A, Murphy GP, Winchester DP. Clinical highlights from the National Cancer Data Base: 1997. *CA Cancer J Clin* 47:161-170, 1997.
95. Evans D, Jessup JM, Colacchio T. Gastric Cancer Surgical Practice Guidelines. Society for

Surgical Oncology. *Oncology* 11:1067-1072, 1997.

96. Evans D, Jessup JM, Colacchio T. Pancreatic Cancer Surgical Practice Guidelines. Society for Surgical Oncology. *Oncology* 11:1074-1079, 1997.
97. Kim HK, Jessup JM, Beard CJ, Bornstein B, Cady B, Stone MD, Bleday R, Bothe A Jr, Steele G Jr, Busse PM. Locally advanced rectal carcinoma: pelvic control and morbidity following preoperative radiation therapy, resection, and intraoperative radiation therapy. *Int. J. Radiat. Oncol. Biol. Phys.* 38:777-783, 1997.
98. Edmiston KH, Gangopadhyay A, Shoji Y, Nachman AP, Thomas P, Jessup JM. In vivo induction of murine cytokine production by carcinoembryonic antigen. *Cancer Res* 57:4432-6, 1997.
99. Menck HR, Cunningham MP, Jessup JM, Eyre HJ, Winchester DP, Scott-Conner CE, Murphy GP. The growth and maturation of the National Cancer Data Base. *Cancer* 80:2296-304, 1997.
100. Jessup JM, Loda M, Bleday R. Clinical and molecular prognostic factors in sphincter-preserving surgery for rectal cancer. *Semin. Radiat Oncol* 8:54-69, 1998.
101. Jessup JM. Tumor markers--prognostic and therapeutic implications for colorectal carcinoma. *Surg Oncol.* 1998;7:139-51.
102. Edmiston KH, Shoji Y, Mizoi T, Ford R, Nachman A, Jessup JM. Role of nitric oxide and superoxide anion in elimination of low metastatic human colorectal carcinomas by unstimulated hepatic sinusoidal endothelial cells. *Cancer Res* 58:1524-31, 1998.
103. Cady B, Jenkins RL, Steele GD Jr, Lewis WD, Stone MD, McDermott WV, Jessup JM, Bothe A, Lalor P, Lovett EJ, Lavin P, Linehan DC. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. *Ann Surg* 227:566-71, 1998.
104. Jessup JM, Stewart AK, Menck HR. The National Cancer Data Base report on patterns of care for adenocarcinoma of the rectum, 1985-95. *Cancer* 83:2408-18, 1998.
105. Jessup JM, Battle P, Waller H, Edmiston KH, Stolz DB, Watkins SC, Locker J, Skena K. Reactive nitrogen and oxygen radicals formed during hepatic ischemia-reperfusion kill weakly metastatic colorectal cancer cells. *Cancer Res* 59:1825-9, 1999.
106. Jessup JM, Ishii S, Mizoi T, Edmiston KH, Shoji Y. Carcinoembryonic antigen facilitates experimental metastasis through a mechanism that does not involve adhesion to liver cells. *Clin Exp Metastasis.* 17:481-8, 1999.

107. Belluco C, Frantz M, Carnio S, Plebani M, Nitti D, Lise M, and Jessup JM. IL-6 blood level is associated with circulating CEA and prognosis in patients with colorectal cancer. *Annals of Surgical Oncology* 7:133-138, 2000.
108. Jessup JM, Frantz M, Sonmez-Alpan E, Locker J, Skena K, Waller H, Battle P, Nachman A, Weber ME, Thomas DA, Curbeam RL, Jr., Baker TL, Goodwin TJ. Microgravity culture reduces apoptosis and increases the differentiation of a human colorectal carcinoma cell line. *In Vitro Cell Dev Biol-Animal* 36:367-373, 2000.
109. Siragusa T, Miller AR, Belluco C, Nitti D, Lise M, Jessup JM. The role of circulating cytokines in colorectal carcinoma. *Int. J. Clin. Oncol.* 5:217-228, 2000.
110. Lee YJ, Lee KH, Kim HR, Jessup JM, Seol DW, Kim TH, Billiar TR, Song YK. Sodium nitroprusside enhances TRAIL-induced apoptosis via a mitochondria-dependent pathway in human colorectal carcinoma CX-1 cells. *Oncogene*. 20:1476-85, 2001.
111. Lee YJ, Galoforo SS, Battle P, Lee H, Corry PM, Jessup JM. Replicating adenoviral vector-mediated transfer of a heat-inducible double suicide gene for gene therapy. *Cancer Gene Ther* 8:397-404, 2001.
112. Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. *J Clin Oncol.* 19:1865-78, 2001.
113. Moon BK, Lee YJ, Battle P, Jessup JM, Raz A, Kim HR. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: implication of galectin-3 function during metastasis. *Am J Pathol.* 159:1055-60, 2001.
114. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. *N Engl J Med.* 345:725-30, 2001.
115. DeArmond D, Brattain MG, Jessup JM, Kreisberg J, Malik S, Zhao S, Freeman JW. Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. *Oncogene*. 22:7781-95, 2003.
116. Jessup JM, Laguinge LM, S. Lin S, Samara R, Aufman K, Battle P, Frantz M, Edmiston KH, Thomas P. Carcinoembryonic antigen induction of IL-10 and IL-6 inhibits hepatic ischemic/reperfusion injury to colorectal carcinoma cells. *Int. J. Cancer* 111:332-337, 2004.

117. Laguinge LM, Lin S, Samara RN, Salesiotis AN, Jessup JM. Nitrosative Stress in Rotated Three-Dimensional Colorectal Carcinoma Cell Cultures Induces Microtubule Depolymerization and Apoptosis. *Cancer Res.* 64 (8):2643-8, 2004.
118. Henke RT, Haddad BR, Kim SE, Rone JD, Mani A, Jessup JM, Wellstein A, Maitra A, Riegel AT. Overexpression of the nuclear receptor coactivator AIB1 (SRC-3) during progression of pancreatic adenocarcinoma. *Clin. Cancer Res.* 10(18 Pt 1):6134-42, 2004.
119. Jessup JM, Samara R, Battle P, Laguinge LM. Carcinoembryonic antigen promotes tumor cell survival in liver through an IL-10-dependent pathway. *Clin. Exp. Metastasis.* 21:709-17, 2004.
120. Jessup JM, Stewart A, Greene FL, Minsky BD. Adjuvant Chemotherapy for Stage III Colon Cancer: Implications of Ethnicity, Age and Differentiation. *JAMA* 294:2703-11, 2005.
121. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC Jr; ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. *J Clin Oncol.* 24:5313-27, 2006.
122. Samara RN, Laguinge LM, Jessup JM. Carcinoembryonic antigen inhibits anoikis in colorectal carcinoma cells by interfering with TRAIL-R2 (DR5) signaling. *Cancer Res.* 67:4774-82, 2007.
123. Laguinge LM, Samara RN, Wang W, El-Deiry WS, Corner G, Augenlicht L, Mishra L, Jessup JM. DR5 receptor mediates anoikis in human colorectal carcinoma cell lines. *Cancer Res.* 68:909-17, 2008.
124. Tang Y, Kitisin K, Jogunoori W, Cuiling Li C, Deng C-X, Mueller S, Ransom H, Rashid A, Ruth He AR, Mendelson JS, Jessup JM, Shetty K, Zaslloff M., Mishra B., Reddy EP, Johnson L, Mishra L. Progenitor/stem cells give rise to liver cancer due to aberrant TGF- β and IL-6 signaling. *Proc. Natl. Acad. Sci. (USA)* 105(7):2445-50, 2008.
125. Washington MK, Berlin J, Branton PA, Burgart LJ, Carter DK, Fitzgibbons PL, Frankel WL, Jessup JM, Kakar S, Minsky B, Nakhleh RE, Compton CC; Cancer Committee, College of American Pathologists. Protocol for the examination of specimens from patients with primary carcinomas of the colon and rectum. *Arch Pathol Lab Med.* 132:1182-93, 2008.
126. Jessup JM, Compton CC, Washington MK. Reply to Editor. *Arch Pathol Lab Med.* (In Press).
127. Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, Zaslloff M, Marshall JL, Shetty K, Johnson L, Mishra L, He AR. The STAT3 inhibitor NSC 74859 is effective in

hepatocellular cancers with disrupted TGF-beta signaling. *Oncogene*. 2009 Jan 12. [Epub ahead of print]

128. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL. American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients with Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy. *J. Clin Oncol* (Epub ahead of print).

2. Reviews or Editorials

1. Ota DM, Jessup JM. Sphincter-saving therapies for low rectal tumors. *The Cancer Bulletin*. 40:226-8, 1988.
2. Jessup JM. Active specific immunotherapy for human colorectal carcinoma. *The Cancer Bulletin*. 40:222-5, 1988.
3. Jessup JM, Thomas P. Carcinoembryonic antigen: function in metastasis by human colorectal carcinoma. *Cancer and Metastasis Reviews*. 8:263-80, 1989.
4. Thomas P, Toth CA, Saini KS, Jessup JM, Steele G Jr. The structure, metabolism and function of the carcinoembryonic antigen gene family. *Biochemica et Biophysica Acta* 1032:177-89, 1990.
5. Jessup JM. Transanal Excision of Early Rectal Carcinoma of the Bowel: Discussion. *Postgraduate General Surgery*. 3:61-2, 1991.
6. Jessup JM and Gallick GE. The biology of colorectal cancer. *Current Problems in Cancer*. 16:261-328, 1992.
7. Jessup JM, Posner M, Huberman M, LoCicero J III, Stone M, Steele G Jr. Efficacy of multimodal therapy in gastric adenocarcinoma. *Sem Surg Oncol*. 9:19-26, 1993.
8. Jessup JM, Posner M, Huberman M. Influence of multimodality therapy on the management of pancreas carcinoma. *Sem in Surg Oncol*. 9:27-32, 1993.
9. Posner MR, Bleday R, Huberman M, Jessup JM, Busse P, Steele G Jr. Impact of combined modality therapy on the treatment of adenocarcinoma of the colon. *Sem Surg Oncol*. 9:33-38, 1993.

10. Jessup JM, Bleday R, Busse P, Steele G Jr. Conservative management of rectal carcinoma: The efficacy of a multimodal approach. *Sem Surg Oncol.* 9:39-45, 1993.
11. Busse PM, Jessup JM, Cady B, Bothe A Jr, McDermott WV, Stone MD, Steele G Jr. Effect of combined modality therapy on the surgical management of locally advanced rectal carcinoma. *Sem Surg Oncol.* 9:46-50, 1993.
12. Spaulding GF, Jessup JM and Goodwin TJ. Advances in cellular construction. *J Cell Biochem.* 51:249-51, 1993.
13. Jessup, JM, The *Annual Meeting* Oncogene (Colon and Pancreatic Cancer).Educational Program. American College of Surgeons. 12-15, 1993.
14. Jessup JM. Commentary on cathepsin B and other proteases in human colorectal carcinoma. *Am J Path* 145:253-262, 1994.
15. Jessup JM. Role of Urokinase, its receptor, and serpins in colorectal carcinoma. Editorial. *Gastroenterology* 107:1555-1559, 1994.
16. Jessup JM. Is bigger better? Editorial. *J Clin Onc* 13:5-7, 1995.
17. Jessup, JM, Steele, GD, Jr, Winchester, DP. Introduction, In: National Cancer Data Base: *Annual Review of Patient Care 1995*. Atlanta, GA; American Cancer Society, pp.1-11, 1995.
18. Jessup JM. Conservative Management of Rectal Carcinoma. *Focus & Opinion: Oncology.* 1: 383-395, 1996.
19. Jessup JM, Loda M. Prognostic markers in rectal carcinoma. *Semin Surg Oncol* 15:131-40, 1998.
20. Jessup JM, Pellis NR. NASA Biotechnology: Cell Science in Microgravity (Editorial on lymphocyte dysfunction in a NASA Bioreactor that simulates microgravity). *In Vitro Cell Dev Biol Anim* 2001 ;37:2 p preceding 63.
21. Jessup JM, Pellis NR. NASA Biotechnology: Cell science in Microgravity (Editorial on use of a NASA Bioreactor that simulates microgravity to analyze normal and malignant tissue constructs). *In Vitro Cell Dev Biol Anim.* 2001;37:2 p preceding 121.

22. Jessup JM, Pellis NR. NASA Biotechnology: Cell science in Microgravity (Editorial on alterations in circulating blood cell function in a NASA Bioreactor that simulates microgravity). *In Vitro Cell Dev Biol Anim.* 2001;37:2 p preceding 203.
23. Jessup JM, Lively TG, Taube SE. Program for the Assessment of Clinical Cancer Tests (PACCT): Implementing Promising Assays into Clinical Practice. *Expert Review Molecular Diagnostics* 5:271-273, 2005.

3. Books and Other Monographs

1. Cohen MH, Felix EL, Jessup JM, Rosenberg SA. Treatment of metastatic melanoma by intralesional injection of BCG, organic chemicals and C parvum. In: *Neoplasm Immunity: Mechanisms*, ed. Crispin RG. Chicago, IL: I.T.R. Press, 1976; 121-34.
2. Jessup JM, Brandhorst JS, Peters LC, Hanna MG Jr. The splenic influence on BCG-mediated therapy in a syngeneic guinea pig tumor model. In: *Immuno-aspects of the Spleen*, ed. Battisto JR, Streilenin M. Amsterdam: North Holland Publishing Co, 1976; 392-8.
3. Fidler IJ, Jessup JM, Kleinerman ES, Fogler WE, Mazumder A. Circumvention of neoplastic heterogeneity by systemically activated macrophages. In: *Biology and Treatment of Colorectal Cancer*, ed. Mastromarino AJ. Boston: Martinus Nijhoff Publishing, 1986; 311-22.
4. Giavazzi R, Jessup JM, Pathak S, Morikawa K, Fidler IJ. Tumorigenic and metastatic properties of human colon carcinomas transplanted into nude mouse. In: *Colon Cancer Cells*, ed. Moyer MP, Poste GH. Florida: Academic Press, 1986.
5. Fidler IJ, Morikawa K, Pathak S, Giavazzi R, Jessup JM. Gastrointestinal cancer: Current approaches to diagnosis and treatment. In: *Annual Clinical Conference on Cancer*, Austin, Texas: U.T. Press, 1988; 30:87-105.
6. Jessup JM, Babcock GF. Current status of adjuvant immunotherapy for human colorectal carcinoma. In: *U.T. Cancer Series: Gastrointestinal Cancer*, ed. Levin. Austin, Texas: U.T. Press, 1988; 191-9.
7. Giavazzi R, Jessup JM, Pathak S, Morikawa K, Fidler IJ. Tumorigenic and metastatic properties of human colorectal carcinomas transplanted into nude mouse. In: *Colon Cancer Cells*, ed. Fidler IJ. New York: Academic Press, 1990; 311-39.

8. Jessup JM, Steele G Jr. Management of Rectal and Anal Carcinoma. In: General Surgical Oncology, ed. Steele G Jr, Cady B. Philadelphia: W.B. Saunders, 1992; 171-84.
9. Jessup JM, Steele G Jr. Rectal Preservation Techniques. In: Atlas of Surgical Oncology, ed. Daly J, Cady B. St. Louis: C.V. Mosby, 1992; 489-500.
10. Jessup JM, Bothe A, Stone MD, Gray C, Bleday R, Busse P, Huberman M, Mayer RJ, Steele G Jr. Preservation of sphincter function in rectal carcinoma by a multimodality approach. In: Surgical Oncology Clinics of North America, ed. Cady B, Jessup JM. Philadelphia: W.B. Saunders, 1992; 1:137-45.
11. Jessup JM. "Conservative Treatment of Rectal Carcinoma." Guest Editor. Surgical Oncology Clinics of North America, Consulting Ed. Cady B. Philadelphia: W.B. Saunders, 1:1-156, 1992.
12. Jessup JM, Steele G Jr. Carcinoma of the Rectum or Anus. In: Surgical Decision Making, 3rd Edition, ed. Norton L, Steele G Jr, Eisman BE. Philadelphia: W.B. Saunders, 1993;166-7.
13. Jessup JM, Steele G Jr. Rectal Carcinoma. In: Current Therapy in Oncology, ed. Niederhuber JE. Philadelphia: B.C. Decker, 1993; 432-6.
14. Jessup JM. Cancer Immunology. In: Current Practice of Surgery, ed. Copeland EM, Levine BA. New York: Churchill Livingstone, 1993; II(4): 3-12.
15. Jessup JM. Tumor Markers: Prognostic and therapeutic implications. In: Colorectal Cancer, ed. Wanebo HJ. Chicago: Mosby-YearBook, Inc., 1993; 106-129.
16. Jessup JM. Clinical Prognostic Factors in Resectable Colonic and Rectal Cancer Patients. In: Cancer of the Colon, Rectum and Anus, eds. Cohen AM and Winawer St. New York: McGraw-Hill Inc., 1994; 217-224.
17. Jessup JM. Duodenal and Pancreatic Carcinomas. In: General Surgery. ed. Ritchie, WP, Steele, Jr G, Dean RH. Philadelphia: J.B. Lippincott, 1994; 235-256.
18. Jessup J, Steele G, Thomas P, Summerhayes I, Mercurio A, Andrews C, Chen L-B, Kolodner R. Molecular Biology of Neoplastic Transformation of Large Bowel: Identification of Two Pathways. In: Surgical Oncology Clinics of North America, ed. Lynch HT, Fitzgibbons RJ. Philadelphia: W.B. Saunders, 1994; 3:449-477.
19. Jessup JM. Introduction. In "Success Stories: Using Comparative Data to Improve Cancer Patient Care. Ploetz BM, Fremgen A, and Menck HR. American College of Surgeons, Chicago

IL, 1995, pp. 11-13.

20. Jessup JM. Management of rectal carcinoma. In: Surgery for Gastrointestinal Cancer: A Multidisciplinary Approach. Ed. Wanebo HJ. Philadelphia: J.B. Lippincott, 1997. pp 689-700.
21. Jessup JM, Steele GD Jr. Extremity Soft Tissue Sarcoma. In "Tumor Board Management", Eds. Winchester D, Brennan MF, Dodd GF Jr., Henson DE, Kennedy BJ, Steele GD Jr., Wilson JF. Lippincott-Raven Publishers, Philadelphia, 1997, pp 333-336.
22. Jessup JM and Thomas P, CEA and Metastasis: A facilitator of site-specific metastasis. In "Cell Adhesion and Communication Mediated by the CEA Family: Basic and Clinical Perspectives." Ed. L. Stanners, Harwood Academic Publishers, Amsterdam, pp 195-222, 1998.
23. Jessup JM, Liu B, and Gallick GE. Molecular Biology Of Colorectal Carcinoma: The Importance Of The Wingless (Wg)/Wnt Signal Transduction Pathway. In "Molecular Basis of Human Cancer." Ed. Coleman and Tsongalis, Humana Press, Totawa, NJ pp.251-268, 2001.
24. Jessup JM, Compton C, Greene, F, et al. Colon and Rectum *in* "Sixth Edition of the American Joint Committee on Cancer TNM Staging Manual," the American Joint Committee on Cancer, Springer-Verlag Publishers, Berlin Eds. GreeneFL, Page, DL, Fleming ID, Fritz AG, Balch CM, Haller DG, and Morrow, M. 2002, pp. 113-123.
25. Jessup JM. Chapter 9: Therapeutic Principles of Gastrointestinal Neoplasia: Emerging therapies: Vaccines. *In* "The Principles and Practice of Gastrointestinal Oncology." Ed. Abbruzzese JL, Evans DB, Willett C, Fenoglio-Preiser C. Oxford University Press, 2004, pp. 102-111.
26. Jessup JM, Gunderson L. et al. Colon and Rectum *in* "Seventh Edition of the American Joint Committee on Cancer TNM Staging Manual," the American Joint Committee on Cancer, Springer-Verlag Publishers, Berlin Eds. Edge S et al Eds. In Press.
27. Sobin L, Compton CC, Jessup JM, et al. Appendix *in* "Seventh Edition of the American Joint Committee on Cancer TNM Staging Manual," the American Joint Committee on Cancer, Springer-Verlag Publishers, Berlin Eds. Edge S et al Eds. In Press.
28. Welton M, Weiser M Aguilar-Garcia J, Jessup JM, et al. Anus *in* "Seventh Edition of the American Joint Committee on Cancer TNM Staging Manual," the American Joint Committee on Cancer, Springer-Verlag Publishers, Berlin Eds. Edge S et al Eds. In Press.

4. Abstracts And Presentations (Partial List)

1. Jessup JM, Madden RE. Further evidence of nonspecific rejection in hosts immunized with non-crossreacting tumors. *Proc Am Assoc Cancer Res.* 12:55, 1971.
2. Jessup JM, Madden RE. Enhancement of tumor syngraft growth by immunogenic tumors and antiserum. *Proc Am Assoc Cancer Res.* 13:64, 1972.
3. Jessup JM, Helson L. Enhancement of tumor growth with DNCB in mice. *Proc Am Assoc Cancer Res.* 15:66, 1974.
4. Jessup JM, Felix EL, Cohen MH. Murine dinitrochlorobenzene (DNCB) reactivity: Depression by melanoma lymphoma and tumor-associated serum factors. *Proc Am Assoc Cancer Res.* 16:97, 1975.
5. Felix EL, Jessup JM, Lloyd BD, Cohen MH. The effect of intraperitoneal Vitamin A on the development of transplantable melanoma. *Assoc Acad Surg.* 1975.
6. Jessup JM, Cohen MH. Splenic sequestration as mechanism of anergy to dinitrochlorobenzene (DNCB) in tumor-bearing (TB) mice. *Proc Am Assoc Cancer Res.* 17:76, 1976.
7. Jessup JM, Riggs CS, Hanna MG Jr. The influence of pre-existing tumor immunity on BCG immunotherapy of guinea pigs with both regional and disseminated tumor. Presented at Thirteenth Annual Meeting of Society of Surgical Oncology, Inc. 1977.
8. Jessup JM, Riggs CW, Hanna MG Jr. The effect of tumor burden and tumor immunity on BCG immunotherapy of a guinea pig hepatocarcinoma. *Proc Am Assoc Cancer Res.* 18:54, 1977.
9. Hanna MG, Jessup JM, Peters LC, Brandhorst JS. A model system for analyzing immunotherapeutic response. Presented at the VI International Congress for Immunobiology in Sydney, Australia. 1977.
10. Jessup JM. Stimulation of tumor colony formation by peritoneal exudate cells. *Proc Am Assoc Cancer Res.* 19:31, 1978.
11. Jessup JM, Lin S-N, Floyd M, Caprioli R, Kahan BD. Quantitation of serum azathioprine levels in transplant patients. *Assoc Acad Surg.* 1978.
12. Jessup JM, Pellis NR, Kahan BD. Suppressor cells in tumor-bearing mice. *Assoc for Acad Surg.* 1979.

13. Jessup JM, Pellis NR, Kahan BD. In vivo suppressor cell activity in tumor-bearing mice. Proc Am Assoc Cancer Res. 21:226, 1980.
14. Jessup JM. Nonspecific suppressor cells in tumor-bearing (TB) mice. Twenty second annual University Surgical Resident's Conference. 1980.
15. Jessup JM, Kahan BD, Pellis NR. Further evidence for nonspecific suppressor cells in tumor-bearing mice. Proc AM Assoc Cancer Res. 22:312, 1981.
16. Jessup JM. Facilitation of tumor growth in an agarose assay. Fed Proc. 40:1151, 1981.
17. Jessup JM, Babcock GF. Immunobiologic significance of clonogenic growth of human colorectal cancer (CRC). (Stem Cells). 1981.
18. Jessup JM, Kahan BD, Pellis NR. Nonspecific suppressor cells: Modulation of hyporesponsiveness in tumor-bearing mice to dinitrochlorobenzene. Ann of N.Y. Acad Science. 298:298, 1982.
19. Jessup JM. Markers of colonic cell differentiation. Proceedings of a conference held in Southwest Harbor, Maine, September 22-24, 1982. Raven Press, Publ., 1982.
20. Jessup JM. 1972-1982: A decade of achievements and challenges in large bowel cancer research. Mastromarino AJ, Brattain MG, (eds.). Proceedings of a conference held in Houston, Texas, June 23-26, 1983. Praeger Scientific, Publ., 1983.
21. Jessup JM, Pellis NR. Tumor-derived suppressor factor (TDSF) induces suppressor cells (SC) for tumor immunity. Lymphokine Res. 3:91, 1984.
22. Giavazzi R, Campbell D, Jessup JM, Fidler IJ. The use of nude mice to determine the metastatic potential of human colorectal carcinomas of recent origin. Proc. Am Assoc Cancer Res. 26:58, 1985.
23. Hoagland JG, Giavazzi R, Jessup JM. Characterization of acid suppressor factors (SFs) from human colorectal carcinomas (CRC) and normal mucosa (NM). Proc Am Assoc Cancer Res. 26:286, 1985.
24. Mazumder A, Fogler W, Jessup JM, Fidler IJ. Activation of colon cancer patients' monocytes by lymphokines and muramyl dipeptide (MDP). Proc Am Assoc Cancer Res. 26:306, 1985.

25. Jessup JM, Guevara J, Babcock GF. Collagenase-DNase digest are a source of autologous tumor-associated antigens (TAA) in human colorectal carcinoma (CRC). UCLA Symposia on Molecular and Cellular Biology, Steamboat Springs, Colorado, January, 1986.
26. Jessup JM, Guevara J, Babcock GF. Isolation of tumor-associated antigens (TAA) from collagenase-dnase digest of human colorectal carcinoma (CRC). Sixth International Congress of Immunology, Toronto, Canada, July, 1986.
27. Jessup JM, Giavazzi R, Campbell DC, Morikawa K, Fidler IJ. Tumorigenicity of human colorectal carcinomas in nude mice is associated with elevated serum CEA. Gordon Research Conference on Cancer, New London, New Hampshire, August, 1986.
28. Jessup JM. Active specific immunotherapy for human colorectal carcinoma. 4th Conference on Modern Approaches to Vaccines, Cold Spring Harbor, New York, September, 1986.
29. Jessup JM, Giavazzi R, Campbell DC, Morikawa K, Cleary K, Fidler IJ. Tumorigenicity of human colorectal carcinomas in nude mice is associated with elevated serum CEA. 20th Annual Meeting of the Association for Academic Surgery, Washington, D.C., November, 1986.
30. Hutchins JT, Jessup JM, Reading CL. Demonstration of altered sialic acid expression in human neoplastic colon. UCLA Symposium, Keystone, Colorado, 1987.
31. Jessup JM, Kanellopoulos K, Qi K, Savage HE. Restricted expression of tumor-associated antigens (TAA) on human colorectal carcinomas: Implications for a Generic Vaccine. SSO, London, England, 1987.
32. Jessup JM. Adjuvant active specific immunotherapy (ASIT) enhances cell-mediated immunity to autologous human colorectal carcinoma (CRC). Am Assoc Cancer Res. 28:361, 1987.
33. Jessup JM, Campbell DE, Qi K. A molecular approach to a generic vaccine for human colorectal carcinoma: Identification of altered cytokeratin as autoantigen. Cold Spring Harbor Laboratory Meetings, Cold Spring Harbor, New York, 1987.
34. Jessup JM, Qi K, Campbell DE. Polypeptide autoimmunogens in human colorectal carcinomas. Second Conference on Immunity to Cancer, Williamsburg, Virginia, 1987.
35. Murray JL, Patt YZ, Lamki LM, Shanken LJ, Jessup JM, Halverson CA, Schweighart S, Unger MW. Detection of occult adenocarcinoma (AdenoCa) by ¹¹¹In-Anti-CEA monoclonal antibody (Mab) ZCE 025 in patients (Pts) with elevated serum CEA. Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer, San Diego, California, 1988.

36. Patt Y, Lamki L, Jessup JM, Levin B, Ajani J, Halverson C, Schweighart S, Shanken J, Murray L. Detection of occult metastatic (mets) adenocarcinoma (AC) in patients with rising serum CEA (RS-CEA) by ¹¹¹In Labeled monoclonal anti-CEA ZCE-025 (MoAb). AACR. 1988.
37. Jessup JM, McCready DR, Rich TA, Thielvoldt D, Ota DM. Phase I study of conservative management of low rectal lesions. Presented at the 41st Meeting of the Society of Surgical Oncology, New Orleans, Louisiana, May 22-25, 1988.
38. Jessup JM, Campbell DE, Morikawa K, Fidler IJ. Role of lymph nodes as reservoirs for metastatic progenitor cells in human colorectal carcinoma. Proc Am Soc Clin Oncol. 7:94, 1988.
39. Chi K-F, Hostetter R, Campbell DE, Kerckhoff S, Murray JA, Haspell MV, Fidler IJ, Jessup JM. Altered expression of soluble cytokeratin 18 in human colorectal carcinoma (CRC): Association with prognosis and growth potential. Proc Am Assoc Ca Res. 29:64, 1988.
40. Jessup JM, Chi-K-F, Hostetter R. Protective tumor-associated autoantigens (TAAA) in colorectal carcinoma. J Cell Biochem Suppl. 12E:145, 1988.
41. Jessup JM, Goodwin TJ, Bucana CD, Sams CF, Wolf DA. Matrix association culture system (MACS): A new three-dimensional culture system for growth factor analysis. J Cell Biol. 107:428a, 1988.
42. Jessup JM, McCready DR, Ota DM, Thielvoldt D, Rich TA. Phase I study of conservative management of low rectal lesions. Forty-first Annual Cancer Symposium of the Society of Surgical Oncology and Thirty-fourth Annual Meeting of the Society of Head and Neck Surgeons. May 22-25, 1988, New Orleans, LA, p.180.
43. Jessup JM, Giavazzi R, Morikawa K, Campbell DE, Hostetter R, Cleary KR, Atkinson EN, Fidler IJ. Growth of human colorectal carcinoma (HCC) cells isolated from surgical specimen predicts disease recurrence in patients operated upon for cure. Proc Ann Meet Am Assoc Cancer Res. 30:A920, 1989.
44. Jessup JM, Ota DM, Thielvoldt D, Pearce AN, Abbruzzese JL, Rich TA. Multimodality treatment for conservative management of rectal carcinoma. Proc Ann Meet Am Soc Clin Oncol. 8:A450, 1989.
45. Jessup JM, Wagner, Toth CA, Ford R, Thomas P. Carcinoembryonic antigen may promote metastasis by cell adhesion. Proc Ann Mtg Am Assoc Cancer Res. 31:A388, 1990.

46. Jessup JM, Hostetter RB, Thomas P. CEA may enhance metastasis of human colon carcinomas (HCC) through a cell adhesion mechanism. Seventeenth Meeting of the International Society for Oncodevelopmental Biology and Medicine. Theoretical and Clinical Cancer Research. September 18-22, 1989. Freiberg, FRG, p.23.
47. Meterissian S, Ford R, Toth CA, Thomas P, Steele G, Jessup JM. Carcinoembryonic antigen is an adhesion molecule for colorectal carcinoma. Proc Annu Meet Am Assoc Cancer Res. 32:A432, 1991.
48. Steele G Jr, Busse P, Huberman MS, LeClair JM, Falchuk ZM, Mayer RJ, Bothe A Jr, Ravikumar TS, Stone M, Jessup JM. A pilot study of sphincter-sparing management of enocarcinoma of the rectum. Special International Columbus Meeting on Surgical Oncology. December 3-5, 1992, Genoa, Italy, p. 22
48. Barnard GF, Mori M, Staniunas RJ, Jessup JM, Steele GD Jr. Gastric carcinoma, unlike colorectal carcinoma, does not exhibit increased mRNA expression of selected ribosomal proteins. American Gastroenterology Meeting, San Francisco CA May 10-13, 1992.
49. Puder M, Barnard GE, Mori M, Redman KL, Jessup JM, Steele GD Jr, Chen LB. The ubiquitin-S27a fusion protein is overexpressed in human colon carcinoma but not gastric carcinoma. Molec Biol Cell. 3:20a, 1992.
50. Jessup JM, Brown K, Ishii S, Ford R, Goodwin TJ, Spaulding GF. Simulated microgravity does not alter epithelial cell adhesion to matrix and other molecules. Molec Biol Cell. 3:71a, 1992.
51. Jessup JM, Colacchio T, Valone F, Mayer RJ, Huberman M, Posner M, Busse P, Osteen R, Gray C, Steele G Jr. Phase I/II neoadjuvant trial for locally advanced pancreas adenocarcinoma. Proc Am Soc Clin Oncol 12:201, 1993.
52. Jessup, J.M. Use of Microgravity for Biotechnology and Cell Biology Research. Testimony to Committee on Science, Space and Technology, U.S. House of Representatives, 103rd Congress, Publication 71-327-cc U.S. Government Printing Office, Washington 6/22/1993;72-114.
53. Ishii S, Kim JC, Ford R, Thomas P, Steel G Jr, Jessup JM. CD44 participates in the adhesion of colorectal carcinoma cells to carcinoembryonic antigen. Proc. Am. Assoc. Cancer Res. 34:33, 1993.
54. Kim JC, Ishii S, Ford R, Thomas P, Steele G Jr, and Jessup JM. Epitopes for homotypic binding of human carcinoembryonic antigen also participate in adhesion to extracellular matrix proteins. Proc. Am. Assoc. Cancer Res. 34:34, 1993.

55. Jessup J, Goodwin T. Simulated microgravity improves production of colonic growth factors. AIAA Space Programs and Technologies Conference and Exhibit, September 21-23, 1993, Huntsville, AL. AIAA-93-4098
56. Jessup JM, Colacchio T, Valone F, Mayer RJ, Huberman M, Posner M, Busse P, Osteen R, Gray C, Steele G Jr. Phase I/II neoadjuvant trial for locally advanced pancreas adenocarcinoma. Proc Annu Meet Am Soc Clin Oncol. 12:A595, 1993.
57. Ishii S, Ford R, Kim JC, Steele GD, Jessup JM. Neoplastic transformation of colonic epithelium alters adhesion to carcinoembryonic antigen and extracellular matrix proteins. Society of Surgical Oncology, 46th Annual Cancer Symposium in Conjunction with Society of Head and Neck Surgeons. March 18-21, 1993, Los Angeles, CA, p. 11
58. Jessup, JM, Thomas P, Ford RD, Ishii S. Homotypic adhesion mediated by carcinoembryonic antigen (CEA) in colorectal carcinoma cells involves CD44 and NCA. Keystone Symposium, Cell Surface and Tissue Engineering Meeting, Taos, NM, February, 1994.
59. Ishii S, Kawano K, Nachman A, Ford R, Thomas P, Steele G Jr., Jessup JM. Intrahepatic traffic of human colorectal carcinoma cells studied by high resolution in vivo videomicroscopy. AACR 1994 Annual Meeting, 1994
60. Jessup JM, Fitzgerald W, Polanec J, Ford R., Goodwin T, Spaulding GF, Brown D. CEA production in human colon cancer. 1994 Meeting of the Tissue Culture Association, Research Triangle Park, NC, June, 1994.
61. Jessup JM, Mayer RJ, Huberman M, Posner M, Busse P, Osteen R, Lewis D, Stone M, Cady B, Burgess A, Steele G Jr. 5-Fluorouracil-containing phase II neoadjuvant trials for locally advanced pancreas adenocarcinoma. American Pancreatic Association, Inc. Chicago, Illinois, November, 1994.
62. Jessup JM, Ford R, Nachman A, Gunthert U, Ishii S. CD44 epitopes alter human colorectal carcinoma adhesion to carcinoembryonic antigen (CEA) and to basement membrane proteins. American Society of Cell Biology, San Francisco, California, December, 1994.
63. Ishii S, Katsunori K, Kruskal, Thomas P, Steele, Jr. G, Jessup JM. Carcinoembryonic Antigen (CEA) promotes liver metastasis by increasing human colorectal carcinoma (CRC) survival in periportal venules. Society of Surgical Oncology, 48th Annual Cancer Symposium, Boston, March, 1995.

64. Jessup JM, Andrews CA, Loda M, Mercurio AW, Summerhayes IC, Lavin P, Steele G. Expression of sucrase-isomaltase (S-I) is an independent prognostic marker for human colorectal carcinoma (CRC) associated with p53 mutation. *Proc Annu Meet Am Assoc Cancer Res.* 36:A3734, 1995.
65. Jessup JM, Andrews CA, Loda M, Summerhayes IC, Lavin P, Steele G, Bleday R. Sucrase-Isomaltase (S-I) is an independent prognostic marker for human colorectal carcinoma (CRC). The American Society of Colon and Rectal Surgeons 94th Annual Meeting, Montreal, Quebec, Canada, May, 1995.
66. Bleday R, Breen E, Jessup JM, Sentovich S, Steele G. Prospective evaluation of local excision for small rectal cancer. The American Society of Colon and Rectal Surgeons 94th Annual Meeting, Montreal, Quebec, Canada, May, 1995.
67. Jessup JM, Nachman A., Ford RD. NASA rotating wall vessel (RWV) provides three-dimension cultures with increased CO₂ and acid production. Aerospace Medical Association, Annual Scientific Program. Anaheim, California, May, 1995.
68. JM Jessup, K Edmiston, S Ishii, P Thomas, G Steele Jr. Carcinoembryonic Antigen (CEA) Promotes Liver Metastasis By Human Colorectal Carcinomas: The Fertilizer Corollary to the Seed-Soil Hypothesis of Paget. Presented at Surgical Biology Club I, American College of Surgeons Annual Meeting, New Orleans, LA, Oct 11, 1995.
69. JM Jessup, M Loda, AW Mercurio, IC Summerhayes, PT Lavin. Mutation in P53 is associated with upregulation of sucrase-isomaltase (S-I), an independent prognostic marker for human colorectal carcinoma (CRC). *Cancer: The interface between basic and applied research.* An AACR special Conference. Abstract A-69, Baltimore, MD. Nov. 7, 1995.
70. Gangopadhyay A, Lazure DL, Schulze RW, Jessup JM, Steele G Jr, Thomas P. Carcinoembryonic antigen induces signal transduction in Kupffer cells. *Proc Annu Meet Am Assoc Cancer Res.* 37:A346, 1996.
71. Mizoi T, Shoji Y, Ishii S, Ford R, Nachman A, Jessup JM. A novel CD44 isoform expressed in colorectal carcinoma cells participates in the binding to hyaluronate. *Proc Annu Meet Am Assoc Cancer Res.* 37:A469, 1996.
72. Shoji Y, Mizoi T, Edmiston K, Ford R, Nachman A, Jessup JM. Murine hepatic sinusoidal endothelial cell effect the adhesion and proliferation of human colorectal carcinoma cells. *Proc Annu Meet Am Assoc Cancer Res.* 37:A600, 1996.

73. JM Jessup. Update on Prognostic Markers For Colon Cancer. Presented to the Spring Meeting of the CALGB, Miami Beach, May, 1996.
74. JM Jessup, A Fremgen, H Menck. The National Cancer Data Base (NCDB): Its role in treating and screening for cancer. Presented at the Annual Scientific Meeting of the UICC, Oslo, Norway, Sept., 1996.
75. JM Jessup. Role of the NCDB in the Commission on Cancer. Presented at the First Annual Meeting of the Commission on Cancer, Chicago, IL, Oct.1996.
76. JM Jessup, Y Shoji, T Mitzoi, KH Edmiston. Hepatic sinusoidal endothelial cells (SEC) eliminate metastatic cells by a nitric oxide-dependent mechanism. *Molec. Biol Cell* 1996;Suppl 7:664a. Abstract #3864, Presented at the ASCB meeting, San Francisco, CA, Dec, 1996.
77. KH Edmiston, EB Leof, A Nachman, JM Jessup. G2 arrest induced by rotational shear stress. *Molec. Biol Cell* 1996;Suppl 7:356a. Abstract #2076, Presented at the ASCB meeting, San Francisco, CA, Dec, 1996.
78. JM Jessup, KH Edmiston, EB Leof. Rotation Induces G2/M Checkpoint Restriction In Anchorage-Independent Cells Lacking p21WAF1. Presented at the Keystone Conference on Control of the Cell Cycle, Keystone, Co, Jan, 1997.
79. JM Jessup, KH Edmiston, EB Leof, M. Su. Simulated Microgravity induces G2 arrest in Colon Carcinoma Cells. Presented at the Investigators Working Group Meeting at Houston, TX Feb, 1997.
80. JM Jessup, KH Edmiston, A. Nachman. R. Ford. The Use of the NASA Bioreactor to Cultivate Liver to Assess Microenvironmental Effects on Colorectal Metastasis. Presented at the Investigators Working Group Meeting at Houston, TX Feb, 1997.
81. JM Jessup. Management of Ulcerative Colitis-Associated Neoplasia: The role of prophylactic colectomy. Presented at St. Anne's Hospital. Fall River, MA. March, 1997.
82. JM Jessup. The Prognostic Marker Program of the Beth Israel Deaconess Medical Center, West Campus: Role of APC. Presented at The Gerontology Department Meeting, Dana-Farber Cancer Institute, March 1997.
83. Jessup JM. Genetics Testing in Colorectal Cancer. Southeastern Massachusetts Cooperative Oncology Group Annual Meeting, May 1997.

84. Jessup JM. Participant as Chairman of Biotechnology DWG, NASA HQ in MRAS, May 5, 1997. Washington D.C.
85. Jessup JM, Summerhayes IC, Shibata D, Cangi G, Lavin PT, Mercurio AM, Fogt F, Loda M. Multivariate analysis of tissue-based prognostic markers in stage II - III colorectal carcinoma. *Proc. Am. Soc. Clin Oncol.* 16:910, 1997.
86. Huberman M, Posner M, Steele G Jr., Osteen RT, Stuart K, Jenkins R, Lewis D, Busse PM, Mayer RJ, Jessup JM. Trimodality therapy is associated with longer survival in locally advanced pancreas cancer. *Proc. Am. Soc. Clin Oncol.* 16:1034, 1997.
87. Jessup JM. Molecular Markers in Colorectal Carcinoma. Karmanos Cancer Institute. Detroit, MI May 1997.
88. Jessup JM. "The Role of the Surgeon in Tissue Procurement and Genetics Testing". Invited Speaker. NIH, Bethesda, MD. Building 31, Room 6, Conference on Tissue Banking and Informed Consent, "Informed consent and IRB review: A model for review and discussion". June 2, 1997.
89. Jessup JM. Surgery as adjuvant therapy in Colorectal Carcinoma. Grand Rounds. Lawrence General Hospital. Lawrence, MA. June 1997.
90. Jessup JM. Immunity and colon cancer. Presented at Novel Therapeutic Strategies for the Treatment of Colorectal Carcinoma, San Diego, November, 1998.
91. Jessup JM, Frantz M, Skena K, Waller H. Stationary cultures reduces the apoptosis induced in a human colorectal carcinoma cell by rotation in 1G or μ G. *Proc. 38th ASCB meeting*, abstract 2828, 1998.
92. Jessup, J.M., Battle P., Waller, H., and Skena, K. Reactive nitrogen and oxygen radicals form during hepatic hypoxia-reperfusion and kill weakly metastatic cancer cells. *Proc. Amer. Assoc. Cancer Res.* 40:A2183, 1999.
93. Jessup, J.M. Molecular and pathologic prognostic markers of colorectal cancer. Invited Presentation to the Japan Surgical Society, Fukuoka JN, April, 1999.
94. Jessup JM. Overview of the Biotechnology Program of the Microgravity Research Division, NASA. Formal presentation to the Space Station Utilization Advisory Subcommittee, NASA, Colorado Springs, CO on June 22, 1999.

95. Jessup JM. Use of ISS: A Principal Investigator's Perspective. Invited lecture at AIAA Annual Meeting, Houston, TX October, 2000.
96. J. M. Jessup, P. Battle, K.H. Lee, M. Frantz. Carcinoembryonic Antigen (Cea) Facilitates Colonization Of Liver By Colorectal Carcinoma (CRC) Through An Il-10-Dependent Mechanism. Presented at 2000 Annual Meeting of the AACR, Philadelphia PA
97. Jessup JM, Belluco C, Herrmann H, Alaniz S, von Orsouw N, Vijg J, Fang D, Bertolle R, Nitti D, Lise M. Somatic mutations in APC gene are molecular prognosticators in patients with colorectal carcinoma. Proc. ASCO 20:A1644, 2001.
98. J.M. Jessup, S. Shentu, K. Krueger, L.H. Augenlicht. Short Term Modeled Microgravity Culture of Human Colon MIP-101 Cells Increases Gene Expression by cDNA Microarray Analysis with a G2/M Cell Cycle Arrest due to Reduction in PLK Expression. Presented at the Investigators Working Group Meeting, Houston, TX March, 2001.
99. J.M Jessup. From Bench to Bedside and Back: The Role of CEA As a Facilitator of Colorectal Liver Metastasis. Tumor Biology Lecture Series, Lombardi Cancer Center, September, 2001.
100. Jessup JM, Krueger K, DeArmond D, Freeman J, Sun LZ. Interleukin-6 (IL-6) inhibits apoptosis-mediated by TGF β and oxidative stress in human pancreatic and colorectal carcinoma. Proc. AACR 43:4409A, 2002.
101. J.M. Jessup, K. Krueger. Rotating Wall Vessel (RWV) Models The Role Of Ischemia-Reperfusion In Liver Metastasis By Colorectal Carcinoma (CRC). Presented at the 2002 Investigator's Workshop at NASA Ames Research Center, Palo Alto, CA, March, 2002.
102. J.M. Jessup. Management of Cost Overruns. Fundamental Biology Workshop 2002, NASA Ames Research Center, Palo Alto, CA, April, 2002.
103. J.M. Jessup, "IL-10 Inhibits the Oxidative Stress of Colorectal Metastasis", Society for In Vitro Biology, Orlando, Fl, June 27, 2002.
104. J.M. Jessup, " ", Metastasis Research Society, Chicago, IL, Sept. 20, 2002.
105. J. M. Jessup, Society for Biological Therapy, La Jolla, CA, Nov 7, 2002.
106. J.M. Jessup. Management of Pancreas Cancer, Surgical Grand Rounds, Georgetown University Hospital, Nov. 12, 2002.

107. J.M. Jessup, Astronaut Training, Flight 13A.1 NASA/JSC, Houston TX Nov 19 and Dec, 11, 2002.
108. J.M. Jessup, "IL-6, Is it important for colorectal metastasis?" Special Seminar, Roswell Park Cancer Institute, Buffalo, NY Nov.25, 2002.
109. J. M. Jessup, Reduction in apoptosis and enhancement of differentiation in microgravity cell culture, Presented at the American Society for Cell Biology Annual Meeting, San Francisco CA, Dec. 17, 2002
110. J.M. Jessup, Multidisciplinary Management of Colorectal Liver Metastases. Surgical grand Rounds, INOVA Fairfax Hospital, Jan 15, 2003
111. J.M. Jessup, N.R. Pellis. ISS Cell Science Research: Lessons Learned from CBOSS. Presented at the 2003 Investigators' Working Group, February 22, 2003, Houston, TX.
112. J.M. Jessup, R. Henke, A. Riegel, A. Wellstein. Serum Proteins in Pancreas Cancer: A Case For Early Diagnosis. Presented to the annual Prostate, Lung, Colorectal and Ovarian Screening Meeting in Chicago, IL on Sept. 10, 2003.
113. J.M. Jessup. Sentinel Node Biopsy in Colorectal Carcinoma. Presented at the Annual Meeting of the American Joint Committee on Cancer in Chicago, IL on Sept 14, 2003.
114. J.M. Jessup, D.J. Carey, A. Wellstein. Pleiotrophin/Syndecan Interactions in Pancreas Cancer. Present at the Biannual meeting for the Activities to Promote Research Collaborations in Cancer Research at the Bethesda Marriott, Oct. 31, 2003.
115. A. Salesiotis, J. Kauh, L. Laguinge, S. Lin, J. M. Jessup. Effect of ErbB-2 Inhibition on Pancreatic Carcinoma L3.5sL Cell Cycle Progression and Apoptosis. Presented at the third Annual UTHSCSA Conference on South Padre Island, Nov. 8, 2003.
116. J.M. Jessup. What Should I Have Known About Doing Cell Biology Experiments in Space?. Presented at the Pre-Meeting Workshop of the American Society of Gravitational and Space Biology in Huntsville, AL Nov, 12, 2003.
117. J.M. Jessup, M. Schmidt, S. Lin, R. Samara, L. Laguinge. Modeled microgravity induces reactive Nitrogen and Oxygen Species (RNS and ROS) to damage cytoskeleton and induce apoptosis. Presented at the American Society of Gravitational and Space Biology in Huntsville, AL Nov, 14, 2003.

118. L. Laguinge, A. Salesiotis, S. Lin, R. Samara, J. Kauh, J.M. Jessup. IL-6 Enhances Pancreatic Carcinoma Cell Migration, Survival And Proliferation In The Presence Of erbB-2 Inhibition. Presented at Molecular Targets of Cancer Therapy, Joint AACR-EORTC-NIH Meeting, Nov. 18, 2003.
119. L. Laguinge, S. Lin, M. Schmidt, J.M. Jessup. ROTATIONAL 3-D CULTURES INCREASE APOPTOSIS THROUGH A REACTIVE NITROGEN MECHANISM. Presented at Annual IWG meeting, Feb. 27, 2004 Palo Alto CA.
119. Laguinge L, Lin S, Samara R, Salesiotis A, Jessup JM. Oxidativestress inhibitscarinomacell number through a non-apoptotic but JAK-dependent pathway. Proc. Am. Assoc. Cancer Res. 45:856 (197a), 2004.
120. A.N. Salesiotis, J. Kauh, L. Laguinge, S. Lin, R. Samara, J. M. Jessup. ErbB-2 Kinase Inhibition Induces Transcriptional Repression of Cyclin D1 and Causes G1 Cell Cycle Arrest and Apoptosis in Human Pancreatic Carcinoma. Proc. Am. Assoc. Cancer Res. 45:176 (40a), 2004.
121. J. M. Jessup, B. Minsky, F.L. Greene, A. Stewart. Adjuvant chemotherapy (ACT) in stage III colon cancer: a study of 156,240 patients from 1985 -2001. Proc. Am. Assoc. Clin. Oncol. 23:3533 (253a), 2004.
122. Modulation of Pleiotrophin (PTN)/Anaplastic Lymphoma Kinase (ALK) Affects Growth and Metastasis of Human Pancreas Carcinoma. J. M. Jessup, S. Lin, R. Samara, L. M. Laguinge, E. Bowden, A. N. Salesiotis, A Wellstein. Presented at annual meeting of the Lustgarten Foundation in June, 2004 San Francisco, CA.
123. Laguinge LM, Samara R, Salesiotis A, Jessup JM. Metastatic Potetntial is Associated with Surviving Nitrosative Stress. Abstract B16, Presented at "Redox Signaling in Biology and Disease," ASBMB Conference, Kiawah Island, SC, Oct. 22, 2004.
124. Samara RN, Laguinge LM, Salesiotis AN, Jessup JM. Carcinoembryonic antigen (CEA) inhibits rotational anoikis in human colorectal cancer (CRC) cells. Abstract B24, Presented at "Redox Signaling in Biology and Disease," ASBMB Conference, Kiawah Island, SC, Oct. 22, 2004.
125. Jessup JM, Samara RN, Laguinge LM. Cancer Stem Cells Inhibit Apoptosis Through Glycosylphosphatidyl Inositol (GPI)-linked Proteins. Presented at the Keystone Conference on Stem Cells, Senescence and Cancer, Oct. 25, 2005, Singapore.